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“Hey, what day is this?” 
“It’s Wednesday, its Tuesday I think” 
“I think the tide’s with us” 
“Keep kickin” 
“I used to hate the water” 
“I can’t imagine why” 
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 9 
In recent times, increasing attention has been paid to bioactive peptides 
which positively modulate health. This thesis describes a study of various 
methods to produce such peptides. Initially, the generation of anti-Cronobacter 
spp. peptides by fermentation of milk protein is described. A porcine gut 
isolate, Lactobacillus johnsonii DPC6026 was initially used in an attempt to 
generate two previously described antimicrobial peptides. Phenotypic analysis 
indicated unsatisfactory casein hydrolysis. The genome of the strain was 
sequenced and annotated. Results showed a number of unique features present 
in the microorganism’s genome, most notably a large symmetrical inversion of 
approximately 750kb in comparison with the human isolate L. johnsonii NCC 
533. Genes indicating the presence of extracellular proteinases were not found. 
The data suggest significant genetic diversity and intra-species genomic 
rearrangements within the L. johnsonii species and indicates a host-specific 
divergence of L. johnsonii strains with respect to genome inversion and phage 
exposure. 
Bacillus spp. are widely used in industrial fermentations and the 
generation of commercial protease enzymes. Some strains are also recognised 
as milk powder contaminants. For these reasons a bank of Bacillus strains was 
generated and investigated for caseinolytic ability and subsequent caseicin 
production.  A number of strains were found to produce a high percentage of 
small peptides following fermentation. Two previously characterised 
antimicrobial peptides were generated following fermentation by specific B. 
cereus and B. thuringiensis strains. Peptides generated in this manner retained 
antimicrobial activity against a Cronobacter milk-powder isolate. In 
conclusion, a novel method to produce two antimicrobial peptides is described 
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which concurrently highlights the potential of Bacillus spp. to produce milk-
derived bioactive peptides. 
 Due to the regulatory issues concerning the use of Bacillus-derived 
ingredients in infant foods, a sterile enzymatic method to generate 
antimicrobial peptides from casein is subsequently described. Bioinformatic 
tools were first used to predict candidate industrial enzymes capable of 
liberating antimicrobials from the milk protein casein. Following this, various 
industrial enzymes were experimentally tested against milk proteins. Resultant 
hydrolysates were examined and found to produce peptides with activity 
against Cronobacter spp.. This study establishes a potential industrial-grade 
method to generate antimicrobial peptides. 
  Research has indicated that administration of the incretin peptide GLP-
1 leads to improvement of glycaemic control in type 2 diabetes patients. The 
generation of a recombinant lactic acid bacteria capable of producing an 
analogue of this peptide is described. In-vivo analysis confirmed predicted 
insulinotropic activity. The results indicate a therapy with potential to alleviate 
hyperglycaemia in type 2 diabetics and also illustrate a method using 
bacteriocin producing cellular machinery to generate fusion proteins for the 
improvement of human health. 
In summary, this thesis describes the generation of bioactive peptides 
by bacterial fermentation, tailored enzymatic hydrolysis and recombinant 
bacterial methods. The resultant peptides possessed significant activity. 
Furthermore, the techniques described contribute to bioactive peptide research 
with regards novel methods of production and industrial scale-up. 
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    Chapter 1 
 
Novel approaches to improve the intrinsic microbiological safety of 
powdered infant milk formula. 
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1.1. Abstract 
Human milk is recognised as the best form of nutrition for infants. 
However in instances where breast-feeding is not possible, unsuitable or 
inadequate, infant milk formulae are used as breast milk substitutes. These 
formulae are designed to provide infants with the optimum nutrition for normal 
growth and development and are available in either powder or liquid form. 
Powdered infant formula is widely used for convenience and economic 
reasons. Current manufacturing processes are not capable of producing a sterile 
powdered infant formula. Due to their immature immune systems and 
permeable gastro-intestinal tracts infants are more susceptible to infection via 
foodborne pathogenic bacteria than other age-groups. Consumption of 
powdered infant formula contaminated by pathogenic microbes can be a cause 
of serious illness. In this chapter, we first discuss the current manufacturing 
practices present in the infant formula industry, followed by the pathogens of 
greatest concern, Cronobacter and Salmonella. Finally, methods of improving 
the intrinsic safety of powdered infant formula via the addition of 
antimicrobials such as bioactive peptides, organic acids, probiotics and 
prebiotics are discussed.        
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1.2. Introduction 
Breast milk is recognised as the gold standard (Vandenplas, 2002) in 
infant nutrition and is consistently recommended by national and international 
health organizations for the first year of life (Kent & Doherty, 2014; Riordan & 
Wambach, 2010). Breastfeeding provides all the nutrition required for normal 
infant growth and development, is optimum for infant digestive conditions and 
also increases the affective relationship between infant and mother. Breast milk 
contains a number of immuno-regulatory components that lowers an infant’s 
risk of gastrointestinal and respiratory infections. Although the benefits of 
breastfeeding in providing the optimal balance of nutrients required for infant 
growth and development are widely accepted and human milk is the first 
choice for infants, infant milk formulae (IMF) play a vital role when 
breastfeeding is not sufficient, possible or desirable.  Infant formula is intended 
as an effective substitute and it is formulated to mimic the nutritional 
constituents of breast milk. Newborn infants are particularly vulnerable to 
infection due to immature internal organs and the lack of a developed immune 
system (Lönnerdal, 2012). Also, commensal microorganism which can act as a 
barrier to infection in the digestive tract may yet be established at this early 
stage of life (Chap et al., 2009). IMF requires very high levels of 
microbiological quality and must conform to national and international 
microbiological criteria (Codex Alimentarius Commsion CAC, 2008) due to 
the susceptibility of newborns to bacterial infection (Forsythe, 2005). 
Unfortunately, current manufacturing technologies mean the generation of a 
completely sterile product is impossible meaning intrinsic contamination of 
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IMF may be a cause of possibly serious illness in infants (Codex Alimentarius 
Commsion CAC, 2008).   
Although production of a completely sterile powdered product is not 
feasible, every effort is taken to limit the possibility of contamination. High 
standards of hygiene are maintained throughout the production process and the 
microbiological quality of each batch is closely monitored. Unlike the 
powdered form, the liquid product, which can be in a concentrate or a “ready to 
feed” form, is sterile and so is generally recommended to infants who are at a 
high risk of infection (WHO, 2007). Powdered infant formula (PIF) is not a 
sterile product even if it has been manufactured to hygienic standards (WHO, 
2007) and is not marketed as one (Jason, 2012). It is however a cheaper option 
than the liquid forms of feed and has a longer shelf life. From a manufacturers’ 
perspective, it offers a greater scope for modifying the formula density should 
it be required during production (Agostoni et al., 2004). Processing methods 
and concerns for the microbiological quality used for standard PIF also apply 
to formulae designed for ill children and also follow-up formula (FUF).  
In this article, we review PIF and the problems associated with bacterial 
contaminations, particularly contamination by Cronobacter and Salmonella. 
There is an increasing interest in the development of natural effective 
antimicrobial agents for the preservation of foods due to safety concerns with 
synthetic compounds (Nair, Kumar, Joy, & Venkitanarayanan, 2004). 
Specifically, there is an increasing interest in the use of natural antimicrobials 
for use in PIF with direct action against Cronobacter (Harouna et al., 2014). 
For this reason, we will also discuss the potential of natural additives capable 
of preventing the proliferation of disease causing pathogens in formula, and 
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how these strategies can be implemented with regard to the strict infant 
formula legislation in place.  
 
1.3. Production of powdered infant formula 
Bovine milk is the basis for most infant formulae but contains higher 
levels of fat, minerals and protein compared to human milk so it is skimmed 
and diluted, to more closely resemble human milk composition (Codex 
Alimentarius Commission CAC, 2007; Koletzko et al., 2005). Soy based 
formulae are also available and are widely used but it has been recommended 
that their use be limited due to potentially harmful effects to the infant due to 
the presence of phytoestrogens in the formulae (Badger et al., 2009; Bhatia & 
Greer, 2008) .  
The composition of powdered infant formula (PIF) is strictly regulated 
and each manufacturer must follow established guidelines outlined to them by 
governing bodies. These values are set by the Codex Alimentarius Commission 
(CAC 1979), company-company agreements as well as “in-house” levels 
regarded as workable based upon prior experience (Forsythe, 2005). All the 
major components added to formula (protein, lipids, carbohydrates) have 
minimum and maximum values (Table 1.1.). Ionizing radiation is currently not 
permitted for any reason due to the organoleptic deterioration it would cause 
the product (Codex Alimentarius Commission CAC, 2007; FAO, 2007). Both 
whey and casein are acceptable sources of protein, and individual amino acids 
may be added to improve the formula’s nutritional value. Only L forms of 
these amino acids are allowed. D Forms are not permitted for fear they may 
cause D-lactic acidosis (Connolly & Lönnerdal, 2004). Commercially 
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hydrogenated fats and oils are not allowed. Fructose is avoided due to 
hereditary fructose intolerance present and undiagnosed in some newborns, 
which may have fatal consequences. Many vitamins and minerals have a 
guidance upper level (GUL) amount for inclusion in PIF. These levels are 
designed for nutrients without enough information for a full rigorous risk 
assessment. These components must have an established history of safe use, 
and aid in the infant’s nutrition (Codex Alimentarius Commission CAC, 2007). 
PIF can be produced in one of three different ways, a Dry-mix, Wet-
mix or combined process. In the Dry-mix process, the various formula 
components are received heat-treated separately from suppliers and blended 
together to ensure a uniform blend of nutrients throughout the powder. This 
process is less capital intensive than the Wet-mix process and importantly, 
allows the manufacturing line to be maintained in a dry state for prolonged 
periods of time, denying any pathogens present access to water and thereby 
minimizing the chance of bacterial growth. The microbiological quality of the 
finished product is determined by the individual component ingredients 
received by the manufacturer as in many cases the powder will not receive 
further in-house heat-treatments. For this reason PIF manufacturers who use 
the Dry-mix method try to develop and maintain close relationships with their 
suppliers. After large-scale blending of the individual components the final 
product undergoes a final check to ensure conformance to appropriate 
specifications. A Wet-Mix process involves blending, homogenising and 
pasteurizing all the components together. Due to the inclusion of a heat-
treatment step the microbiological quality of the finished product is far less 
reliant on the base ingredients. This process also ensures the uniform 
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distribution of nutrients throughout each batch. The nature of this process 
requires that manufacturing equipment be routinely wet-cleaned. The presence 
of liquid in the manufacturing environment due to this cleaning can allow the 
growth and establishment of microorganisms. Manufacturers separate their 
plants into strict wet and dry areas and restrict movement of equipment and 
personnel in these areas in an effort to minimize cross-contamination. 
Following pasteurization heat-sensitive micronutrients are added. The 
microbiological quality of these micronutrients is important as further heat-
treatments may not be applied to the product. The liquid mix is then spray-
dried to form a powder. The Combined process involves drying a wet mixture 
of the major formula ingredients (fat, protein and carbohydrates), referred to as 
infant formula base powder. This base powder is then combined with pre-dried 
minor ingredients (vitamins and minerals) and mixed to produce the finished 
product. Regardless of the process used the resultant powder is packed in 
containers, flushed with inert gas, sealed with an airtight cap, coded and 
labelled. Each batch of formula is usually held until samples from it have 
undergone analysis for uniformity, nutritional content and microbiological 
safety (FAO, 2007).  
Various food safety authorities regulate and monitor the components 
and manufacture of PIF and scientific committees advise on whether 
ingredients should be added/removed or whether the amounts of individual 
components should be altered with regard to new research. The Codex 
Alimentarius Commission (CAC) comprises 186 members (185 states and 1 
organisation [European Union, EU]). As well as these countries over 200 non-
governmental organisations and inter-governmental organisations are observers 
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of the CAC. The CAC develops and adopts food standards that serve as 
reference for the international food trade. In many cases Codex standards also 
serve as a basis for national legislation (Codex Alimetarius Commission CAC, 
2013). For EU member states the EU directive 2006/141/EC (this directive was 
recently slightly amended with regard to protein content [Commission directive 
2013/46/EU]) sets values and labelling protocols for the composition of infant 
formulae and follow-on formulae.   
Of note is the fact even if perfectly sterile processes conditions were 
achieved in a factory setting, exposure is more likely to come from the formula 
preparer/caregiver (FAO, 2007). Extrinsic contamination can occur due to use 
of contaminated utensils and equipment in the preparation environment or from 
the preparer and can influence the microbiological safety of both powder and 
liquid infant formulae. In 2007 the World Health Organization (WHO) in 
collaboration with the Food Safety Authority of Ireland (FSAI) and the Food 
and Agricultural Organization of the United Nations (FAO) issued guidelines 
for the safe preparation, handling and storage of PIF. If the formula preparer 
follows such guidelines correctly the potential for infection will be low (WHO, 
2007). However in certain instances, through carelessness or incompetence, 
appropriate guidelines may not be followed. The presence of a microbiological 
protectant in the formula could help maintain a low amount of a pathogenic 
organism following reconstitution and lower the risk of catastrophic infection. 
While microorganisms do not grow in dry PIF, following reconstitution it 
provides an excellent medium for bacterial growth particularly if it is not 
refrigerated. If held for an extended period of time certain microorganisms 
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present in the formula, either due to extrinsic or intrinsic contamination will 
rapidly grow to potentially harmful levels.  
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1.4. Pathogens in Infant Formula  
1.4.1. Introduction 
As previously mentioned PIF is not a sterile product. Milk feeds act as 
excellent media for bacterial multiplication so any pathogens which have 
survived processing or contaminate the product afterward may rapidly multiply 
if given the opportunity post rehydration (Agostoni et al., 2004). A joint 
FAO/WHO consultation group (2004-2006) identified the primary 
microorganisms associated with PIF contamination as Cronobacter sp., 
Salmonella enteritidis, Enterobacter agglomerans, Hafnia alvei, Klebsiella 
pneumoniae, Citrobacter koseri, Citrobacter freundii, Klebsiella oxytoca, 
Enterobacter cloacae, Escherichia coli, Serratia sp., Acinetobacter sp., 
Bacillus cereus, Clostridium difficile, Clostridium perfringens, Clostridium 
botulinum, Listeria monocytogenes and Staphylococcus sp.. Cronobacter sp. 
and Salmonella enterica were identified as the pathogens of most concern in 
PIF. PIF contaminated with either of these organisms has been associated with 
serious illness and death (WHO, 2007).   
 
 
 
 
 
 
 
 
 
 11 
1.4.2. Cronobacter  
Cronobacter are gram-negative, motile, non-spore-forming peritrichous 
rods of the Enterobacteriaceae family (Farmer, Asbury, Hickman, & Brenner, 
1980; FSAI, 2011). Previously referred to as Enterobacter sakazakii, the 
microorganism has recently been formally reclassified as a new genus, 
Cronobacter, currently comprising ten species, Cronobacter sakazakii, 
Cronobacter malonaticus, Cronobacter turicensis, Cronobacter muytjensii, 
Cronobacter dublinensis, Cronobacter universalis, Cronobacter condimenti, 
Cronobacter helveticus, Cronobacter pulveris and Cronobacter zurichensis  
(Holý & Forsythe, 2014; C. Iversen et al., 2007; C. Iversen et al., 2008; Carol 
Iversen et al., 2008; Joseph et al., 2012). Due to the relatively recent 
reclassification, there is uncertainty regarding the specificity of Cronobacter in 
publications prior to 2007. The species can be classified into two groups; 
Group 1 (C. sakazakii and C. malonaticus) and Group 2 (C. turicensis and C. 
universalis). From a healthcare perspective Group 1 species are of more 
importance and form the majority of clinical isolates (Holý & Forsythe, 2014). 
Cronobacter infection represents a serious health risk in infants; 
particularly neonates, and death may occur in 40%-80% of cases (Drudy, 
Mullane, Quinn, Wall, & Fanning, 2006; Gurtler, Kornacki, & Beuchat, 2005; 
Nazarowec White & Farber, 1997). The microorganism has been implicated in 
cases of meningitis, septicemia, and enteritis and is found in sites normally 
sterile in healthy individuals such as blood, bone marrow and cerebrospinal 
fluid in infected individuals (Drudy et al., 2006; Gurtler et al., 2005; C. Iversen 
et al., 2008). Cronobacter infection has also been implicated in cases of 
necrotizing enterocolitis (NEC) which affects 2-5% of all premature infants 
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and is the most common gastrointestinal emergency in neonates (Hunter et al., 
2008; Van Acker et al., 2001). Infected infants are usually treated with 
antibiotics such as ampicillin-gentamicin or ampicillin chloramphenicol (Lai, 
2001). Survivors often suffer from various neurological and/or gastrointestinal 
sequlae such as hydrocephalus, poor neural development (C. Iversen & 
Forsythe, 2003) and short gut syndrome (Hunter et al., 2009). Since 2002 
Cronobacter have been recognized as “Severe for restricted populations, life 
threatening or substantial chronic sequlae for long duration” by the 
International Commission on Microbiological Specification for foods (ICMFS) 
(Forsythe, 2005; ICMFS, 2002) An infectious dose of 10,000 Colony Forming 
Units (CFU) in a single feeding was proposed by the WHO/FAO in 2007 
(WHO/FAO 2008). Although understanding of Cronobacter has increased 
considerably in recent years, there remains unresolved questions regarding its 
pathogenicity and few virulence factors have been identified to date. 
It is likely that the infection route is via attachment and invasion of 
cells in the intestine following consumption. Indeed, gene clusters responsible 
for fimbriae have been identified in a number of Cronobacter genomes. C. 
sakazakii species possess genes which encode for Beta-fimbriae while other 
Cronobacter genomes encode for curli fimbriae (Joseph & Forsythe, 2011; 
Kucerova, Joseph, & Forsythe, 2011) which may reflect a host-influenced 
evolution (Holý & Forsythe, 2014). C. sakazakii alone also utilizes exogenous 
sialic acid, a substance present in breast-milk, mucin and gangliosides 
(glycosphingolipids associated with the central nervous system) which is added 
to infant formula due to its association with brain development (Joseph, Hariri, 
Masood, & Forsythe, 2013). Five putative type VI secretion system (T6SS) 
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gene clusters have been recognized in Cronobacter genomes although 
functional expression of these genes in Cronobacter is yet to be confirmed (C. 
Grim et al., 2012; C. J. Grim et al., 2013; Joseph & Forsythe, 2011). This 
system is recently described and may be involved in cytotoxicity, cell 
adherence/invasion and the ability to survive within the host. A number of 
studies have indicated that outer membrane proteins (omp) A and X have roles 
in invasion and translocation of brain microvascular endothelial cells which 
form the blood-brain barrier (Kim, Bae, & Lee, 2012; Mohan Nair, 
Venkitanarayanan, Silbart, & Kim, 2009). The mechanism(s) responsible for 
brain cell destruction are yet to be elucidated (Holý & Forsythe, 2014).        
The natural reservoir of Cronobacter has not been confirmed and it has 
been isolated from both human and non-human sources. PIF is the food most 
commonly associated with infection. However the source of contamination of 
PIF by Cronobacter is an area of contention (Himelright et al., 2002; Norberg 
et al., 2012). The bacterium has been isolated from both  home (García, 
Notario, Cabanás, Jordano, & Medina, 2012) and hospital environments 
(Flores, Medrano, Sánchez, & Fernandez-Escartin, 2011) as well as milk 
powder processing plants (Craven, McAuley, Duffy, & Fegan, 2010; Müller, 
Stephan, Fricker-Feer, & Lehner, 2013). Cronobacter has also been detected in 
previously unopened PIF products indicative of intrinsic contamination (FAO, 
2007; WHO, 2006, 2007). Certain components of PIF such as starches and 
inulin have been considered as possible sources of contamination (Walsh et al., 
2011). Although it is generally agreed that Cronobacter are relatively 
thermotolerant organisms, they are incapable of surviving pasteurization 
(Strydom, Cawthorn, Cameron, & Witthuhn, 2012) indicating that PIF 
 14 
becomes contaminated downstream of this process (Gurtler et al., 2005; C. 
Iversen & Forsythe, 2003; NazarowecWhite & Farber, 1997) by additional 
ingredients, plant equipment or via asymptomatic carriage of Cronobacter by 
workers in the processing plant. Indeed Cronobacter has been isolated from the 
faeces, skin and mouth of otherwise healthy individuals (Hägg, 
Kaveewatcharanont, Samaranayake, & Samaranayake, 2004; Kandhai et al., 
2010). 
         Regardless of how contamination occurs, once present it is 
estimated that some strains of Cronobacter can survive, dormant in PIF for at 
least two years (C. Iversen & Forsythe, 2003) and rapidly grow upon 
reconstitution (Barron & Forsythe, 2007). Tolerance of desiccated conditions 
for such an extended period of time can be attributed to certain aspects of the 
bacterium’s physiology, perhaps most notably the propensity some strains 
possess to produce a capsule (Barron & Forsythe, 2007; Holý & Forsythe, 
2014). Cronobacter is resistant to desiccation over a wide range of aw (0.25-
0.86). Over a 12 month storage period, the pathogen has been shown to survive 
better in dried formula possessing an aw between 0.25–0.30 than at 0.69–0.82 
(FSAI, 2011). This resistance to osmotic stress may be aided by the organisms 
ability to accumulates solutes such as trehalose which can help stabilize 
membrane components (Breeuwer, Lardeau, Peterz, & Joosten, 2003)  As well 
as protection from desiccation, the capsule material may also protect 
Cronobacter from disinfectant agents (Beuchat et al., 2009) used to clean 
processing plant equipment and preparatory utensils. Upon reconstitution, the 
organism is capable of growth at temperatures from as low as 6°C to as high as 
47°C (C Iversen, Lane, & Forsythe, 2004). Cronobacter can adhere to 
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materials commonly used in food preparation utensils (e.g. silicone, stainless 
steel and polycarbonate) which may increase the chance of extrinsic 
contamination during formula preparation and feeding (Holý & Forsythe, 
2014). Finally, the organism appears to tolerate a broad range of pH conditions 
(pH 4.5-10) which contributes to its survival under various acidic/basic 
conditions (Breeuwer et al., 2003).  
The rise in Cronobacter notoriety has prompted changes in the 
microbiological criteria for PIF and reconstitution procedures. Perhaps most 
notable is the FAO-WHO document (WHO, 2007) “Guidelines for the safe 
preparation, storage and handling of powdered infant formula” which was the 
result of two FAO-WHO meetings held in 2004 and 2006 (Norberg et al., 
2012). The document recommends reconstituting with water which has cooled 
to 70°C from boiling in order to destroy vegetative cells, reconstitute only the 
required amount and reduce the storage period prior to consumption as much as 
possible (WHO, 2007). The use of 70°C water is not adhered to in all countries 
and can be impractical for a number of reasons. For one the insertion of a 
thermometer into the liquid presents another route of possible contamination. 
For this reason caregivers are advised to boil water and let it cool for 30 
minutes which can be impractical (particularly in cases where feeding may be 
required every two hours) and inexact due to extrinsic influences on 
temperature. The use of 70°C (or higher depending on the accuracy the 
caregiver practices) water may also affect the nutritional quality of the formula  
due  to damage to heat sensitive ingredients such as some vitamins and 
probiotics (Holý & Forsythe, 2014).     
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Various microbiological tests are applied to samples from each PIF 
batch which are compared with microbiological criteria outlined by the CAC, 
“in-house” levels deemed workable due to prior experience and company 
agreements (Norberg et al., 2012). Many infant food producers are legally-
bound to implement good manufacturing processes (GMPs) or Hazard 
Analysis Critical Control Point (HACCP) principles into their control plan in 
order to reduce the risk of contamination (Hamrin & Hoeft, 2012). In the USA 
only the state of Minnesota requires reporting of incidences of Cronobacter 
infection (CDC, 2014; Jason, 2012). The incidence rate of infection for the 
USA at least are one per 100,000 infants which rises to 9.4 per 100,000 in 
infants of low birth weight (FAO-WHO, 2006). A 2002 FDA study which 
detected Cronobacter in 23 % of sampled PIF (Jason, 2012), coupled with 
three neonatal intensive (Himelright, 2002; Simmons, Gelfand, Haas, Metts, & 
Ferguson, 1989; Van Acker et al., 2001) care outbreaks which strongly 
implicated PIF as the vehicle of transmission prompted the WHO to announce 
that PIF had strong links microbiologically and epidemiologically to 
Cronobacter infection in infants (FAO, 2007).  The previous FDA method for 
analysis of PIF was based on the most probable number (MPN) approach 
which was then followed by a number of culturing steps which could take a 
week to produce a result. Presumptive Cronobacter isolates were then 
confirmed using biochemical profiling (API) and oxidase tests. In March 2012 
the FDA replaced the chapter “Isolation and Enumeration of Enterobacter 
sakazakii from Dehydrated Powdered Infant Formula” with a chapter 
specifically for Cronobacter in their Bacteriological analytic manual which can 
be located at 
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(http://www.fda.gov/Food/FoodScienceResearch/LaboratoryMethods/ucm2893
78.htm). The new method includes Real-Time Polymerase Chain Reaction 
(RT-PCR) analysis for rapid screening of isolates as well as more traditional 
culture-dependent ones. Positive RT-PCR should be validated using the 
cultural method (Strydom et al., 2012). The FDA are currently implementing 
new rules for PIF manufacturers which include specific testing for Salmonella 
and Cronobacter (FDA, 2014).  
Outbreaks of neonatal Cronobacter infections are hard to document due 
to the difficulty in proving that it was contaminated PIF that caused the 
illnesses. There currently exists no global active surveillance network for this 
pathogen. The FAO/WHO reported 120 incidences of Cronobacter in children 
younger than 3 years old between 1961 and 2008 (Jaradat, Al Mousa, 
Elbetieha, Al Nabulsi, & Tall, 2014). It is estimated that the actual level of 
infection is higher (Control & CDC, 2009). Specific incidences of infant and 
neonatal Cronobacter infection have been recently reviewed elsewhere 
(Norberg et al., 2012). It should be noted that the outbreak (Himelright, 2002) 
which initiated the FAO-WHO risk assessment of Cronobacter and the WHO 
preparation of PIF guidelines was due to a formula product specifically for 
neonates and not regular PIF and as such, is not covered by any new legislation 
related to standard PIF (Holý & Forsythe, 2014). Also of note is the fact that in 
certain instances, children below 6 months of age receive follow-up formula 
(FUF) in error (Chap et al., 2009). Changes to PIF legislation should 
accommodate this malpractice.  
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1.4.3. Salmonella 
Salmonella diverged from a common ancestor with Escherichia 100-
150 million years ago and evolved as an intracellular pathogen (Doolittle, 
Feng, Tsang, Cho, & Little, 1996). The taxonomy and nomenclature of 
Salmonella are controversial, complex and continually evolving. The 
Salmonella genus is composed of two distinct species, Salmonella bognori (a 
cold-blooded vertebrate commensal) and Salmonella enterica, which is divided 
into six sub-species. These sub-species are classified in to 50 serogroups based 
on the somatic (O) antigen, and further divided into over 2,400 serovars based 
on the flagellar (H) antigen. The majority of serovars associated with diseases 
in humans belong to S. enterica subsp. 1. This subspecies causes two types of 
diseases in humans due to ingestion of contaminated foodstuffs or water; 
enteric fever (typhoid) or gastroenteritis. Gastroenteritis is mainly caused by S. 
enteritidis and S. enterica serovar Typhimurium (Sabbagh, Forest, Lepage, 
Leclerc, & Daigle, 2010). Intrinsic contamination of PIF with non-typhoidal 
Salmonella enterica is an important cause of infection and illness in infants 
(FAO, 2007).     
Rates of Salmonella infection are highest in infants less than a year old 
(Jones et al., 2006) In the United States for example, incidence rates in infants 
are eight times higher that rates observed in the adult population. The higher 
incident rate may be due to a higher susceptibility in infants, or the fact that 
infants are more likely to receive medical attention than adults (WHO, 2006). 
Infections for the most part are sporadic (Olsen et al., 2001) but outbreaks 
caused by the pathogen have been recorded (Angulo, Cahill, Wachsmuth, de 
Lourdes Costarrica, & Embarek, 2008; Boehmer et al., 2009). Outbreak 
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detection is usually due an unusual serotype of Salmonella, possessing a trait 
facilitating their detection being responsible for illness (FAO/WHO, 2006). 
Non-typhoidal Salmonella infection can cause gastroenteritis leading to 
diarrhoea, fever and vomiting (Jones et al., 2006) but in certain instances can 
lead to more serious conditions such bacteraemia, septic arthritis, pneumonia 
and meningitis. Due to their immature immune systems, infants infected by 
Non-typhoidal Salmonella are more likely to suffer these debilitating 
potentially fatal diseases (Boehmer et al., 2009; Jones et al., 2006). The 
severity of disease Cronobacter can cause in infants, coupled with its relatively 
recent emergence has caused it to overshadow concerns regarding 
contamination of infant formula with Salmonella (Angulo et al., 2008). It 
should also be noted that in due to the nature of bacterial transmission which 
can occur when an infected individual practices poor hygiene, non-infant 
formula caused illness is far more likely than illness caused by intrinsically 
contaminated PIF. When intrinsic Salmonella contamination does occur, the 
bacteria generally enter infant formula due to contamination by ingredients 
which have not undergone sufficient heat-treatment, or contamination due to 
the processing environment post-thermal treatment (FAO, 2007).  
Control measures implemented by PIF manufacturers are similar to 
those used by other dairy powder manufacturers and are based on 4 principles: 
(1) Avoidance of entry of Salmonella into the processing facilities and in 
particular the zones from drying to filling, considered as high-hygiene area 
(appropriate zoning and segregation); (2),  avoidance of multiplication of 
Salmonella in case of entry (elimination of water); (3) hygienic design of high-
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hygiene zones and the equipment located in such zones; and (4) use of dry-mix 
ingredients which are free of Salmonella. 
  Salmonella infections and outbreaks due to intrinsically contaminated 
PIF are usually only reported in instances where the causal strain is a rare one.   
At least five outbreaks related to intrinsic PIF contamination occurred between 
1985 and 2005. An outbreak occurring in France in 2005 led to 141 confirmed 
cases of illness. A case controlled study conducted to find the source of the 
infection identified a particular infant formula brand as responsible and 
molecular identification techniques provided verification (Brouard et al., 
2007).  This case highlights the importance of surveillance, which in France is 
based on a network of laboratories which voluntarily send isolates to a national 
reference centre to be serotyped. The rare serotype S. enterica Agona, was 
implicated and allowed the source of infection to be traced. In 2008, Spain’s 
National Centre of Microbiology notified an increase in S. kedougou isolates 
from ill children leading to a product recall for the infant formula implicated. 
During the outbreak 31 children (>1 year) became ill and symptoms included 
fever and diarrhoea. Salmonella isolated from the patients showed 
indistinguishable pulse-field gel electrophoresis (PFGE) profiles and identical 
antibiotic resistance profiles. The author’s results indicated that a particular 
brand of PIF was the cause of the outbreak and no further cases were detected 
following its recall. The strain implicated had previously been responsible for 
two outbreaks in the United Kingdom and Norway (meat products were 
implicated in those cases). The authors concluded that the increase in this 
serotype of Salmonella was only detected due to the low-expected frequency of 
it in Spain (Rodríguez-Urrego et al., 2010).  
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Current Codex Alimentarius recommendations indicate a product is fit 
for consumption if sixty 25g samples test negative for microorganisms. 
Salmonella is rarely detected in PIF using this method (Rodríguez-Urrego et 
al., 2010). In one outbreak in 1985, it was reported that Salmonella was present 
in very low numbers (1.6 organisms per 450g) (WHO, 2006). In most 
investigations, the epidemic strain is isolated from bulk samples. Outbreaks of 
salmonellosis due to contaminated PIF are likely underreported due to the 
difficulty in implicating a serotype without a rare trait, a lack of routine 
serotyping in an area or blaming an illness on another factor (WHO, 2006).  
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1.5. Antimicrobial agents 
1.5.1. Bioactive Peptides 
Bioactive peptides are small peptide sequences consisting of 3-50 
amino acid residues (Benkerroum, 2010; H. Korhonen & Pihlanto, 2006). 
These peptides may possess a number of physiological properties including 
opiate, anti-thrombotic, anti-hypertensive and antimicrobial activity in vivo and 
in vitro (Clare & Swaisgood, 2000). These peptide sequences exist in a latent, 
encrypted state in a precursor protein which may be of animal, bacterial or 
plant origin (Smacchi & Gobbetti, 2000) and are released via direct enzymatic 
hydrolysis or fermentation (H. Korhonen & Pihlanto, 2006). To date, hundreds 
of bioactive peptides have been identified and this number continues to grow as 
novel methods of generating peptides are developed (Benkerroum, 2010; 
Rydengård et al., 2008). Milk proteins have been recognised as one of the most 
valuable sources of bioactives (Gill, Lopez-Fandino, Jorba, & Vulfson, 1996; 
H. Korhonen & Pihlanto, 2006) and are generally assured to be safe and 
inexpensive (Benkerroum, 2010). Particular to this article, from a regulatory 
standpoint, the inclusion of dairy-derived bioactive peptides in PIF is not of 
major concern. Indeed, hydrolysed milk protein fragments are already present 
in formulae in the form of hypoallergenic infant formulas (Hannu Korhonen, 
Pihlanto-Leppäla, Rantamäki, & Tupasela, 1998).  
Milk is composed of a number of proteins, the major two being bovine 
casein and whey with casein accounting for 80% of the total protein content 
(Silva & Malcata, 2005). There are 4 major types of casein proteins, αS1-, αS2-
, ß- and ĸ-casein (Malkoski et al., 2001). Whey protein consists of a number of 
globular proteins such as bovine serum albumin and ß-lactoglobulin, isolated 
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from the whey fraction of milk (Farrell et al., 2004). Some whey proteins, such 
as lactoferrin possess inherent antimicrobial properties (Benkerroum, 2010; 
Tomita, Wakabayashi, Yamauchi, Teraguchi, & Hayasawa, 2002).  
Antimicrobial peptides (AMPs) have been recognised as important 
elements of the innate immune system (Kamysz, Okroj, & ukasiak, 2003). 
These peptides are diverse and ancient molecules and are present in various 
sources. Regardless of the source, antimicrobial peptides show similar 
recurrent structural and functional characteristics. These peptides interact with 
bacterial membranes causing disruption leading to rapid cell death (López 
Expósito & Recio, 2006). Most AMPs can adopt an amphipathic conformation 
allowing for interaction with hydrophilic and hydrophobic interfaces on the 
bacterial membrane. Peptides also contain a positively charged domain which 
aides disruption of the negatively charged bacterial membrane (López-
Expósito, Amigo, & Recio, 2008). It is thought that AMPs could also target 
intracellular components of bacteria such as nucleic acids or intracellular 
proteins (Kragol et al., 2001). To date, physiologically active peptides such as 
those possessing angiotensin-1-converting enzyme (ACE)-inhibitory activity 
have been the subject of more scrutiny than antimicrobial peptides 
(Benkerroum, 2010). In the past, healthcare industries had an initial lack of 
interest in antimicrobial peptides due to cost and efficacy in comparison with 
conventional antibiotics (Lahov & Regelson, 1996). However, due to a 
consumer preference for lightly processed foods containing low-levels of 
artificial preservatives and chemicals, AMPs are now being investigated as 
possible natural bio-preservatives (Al-Nabulsi et al., 2009). Although current 
antimicrobials may not be potent enough to use directly as a replacement for 
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traditional antibiotics, the potential to act as a natural prophylactic protectant in 
many foods cannot be underestimated (Benkerroum, 2010). 
One of the best known AMPs is Lactoferrin (LF), which is an 80 kda 
iron-binding molecule (Baldi et al., 2005; López Expósito & Recio, 2006) 
found in neutrophils and most other biological exocrine secretions. It is present 
in the whey component of milk of a number of mammals (Facon & Skura, 
1996). LF is resistant to proteolysis in the gut and can be found intact in the 
faeces of breastfed neonates signifying that initially, it may not have a large 
role to play in infant nutrition (L. A. Davidson & Lönnerdal, 1987; Kuwata et 
al., 2001). The concentration of LF in human milk is 2 mg/ml (although this 
varies during lactation; at points up to 10 mg/ml in colostrum (Actor, Hwang, 
& Kruzel, 2009)) compared 0.02-0.2 mg/ml in bovine milk (Shimazaki, 2000) 
indicating it’s importance to infants. The iron-binding activity of LF allows it 
to inhibit the growth of bacteria, parasites and fungi (Farnaud & Evans, 2003). 
LF is also capable of binding to the surface of Gram-negative bacteria causing 
cell death due to the release of lipopolysaccharide (LPS) from the cell 
membrane (Ellison 3rd, Giehl, & LaForce, 1988) which occurs in a 
temperature dependent manner (Al-Nabulsi et al., 2009). Apart from 
antimicrobial properties, the bioactivities of LF include anti-inflammatory, 
anti-cancer and immuno-modulating properties as well as the ability to promote 
the growth of Bifidobacteria (Al-Nabulsi & Holley, 2007).  
A recent study evaluated the antimicrobial activity of LF (of bovine 
origin) on Cronobacter. The authors used both native and iron-saturated LF in 
their antimicrobial assays which were carried out in phosphate buffer, bovine 
whey and bovine skim milk. The results suggest that binding of iron is 
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important for antibacterial activity against the pathogen as native LF was the 
only form which reduced growth (concentration and incubation time-
dependent) in all media tested. The study also demonstrated the protective 
effect that skim milk and whey have for the bacteria in comparison to the 
phosphate buffer which is of importance with regards to PIF. The authors also 
concluded that bovine LF is highly resistant to most standard forms of 
pasteurization (Harouna et al., 2014). Another study demonstrated the anti-
adhesive effect that LF had against a Cronobacter strain originally isolated 
from PIF (C. sakazakii 4603) as intestinal adherence is an important initiator of 
bacterial pathogenesis (Casadevall & Pirofski, 2001; Isaacson, 1982). The 
results indicated that adherence could be significantly reduced (80-99 %) in-
vitro at a concentration of 10 mg/ml LF. The inclusion of an oligosaccharide 
did not increase anti-adhesive activity (Quintero-Villegas, Wittke, & Hutkins, 
2014). Of note, a study by Al-Nabulsi et al. demonstrated that PIF may have an 
inhibitory effect on LF antimicrobial activity, possibly due to the high 
concentration of divalent cations in the powder (Al-Nabulsi et al., 2009) which 
has been shown to reduce the antimicrobial activity of LF against other 
pathogens (Ellison, Giehl, & LaForce, 1988). The authors found that 2.5 mg/ml 
of LF was able to inactivate 4 log
10
 CFU/ml of undessicated Cronobacter cells 
when suspended in peptone water at 37° C. However, there was no detectable 
antimicrobial activity in PIF under the conditions tested. The authors also 
concluded that the high concentration of iron in reconstituted PIF may have 
negated the iron binding ability of LF (Al-Nabulsi et al., 2009). As well as the 
antimicrobial effects exhibited by LF, studies have shown it can have a positive 
effect on outcomes of respiratory disease and levels of red blood cells in 
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circulation when added to infant formula (Francescato, Mosca, Agostoni, & 
Agosti, 2013; King Jr et al., 2007). Recently, an EFSA panel announced that 
bovine LF is safe for inclusion in infant formula at specific concentrations 
(EFSA, 2007).           
In 1992, Bellamy et al., 1992 identified an N-terminal region within LF 
that was antimicrobial. Pepsin digestion of both human and bovine LF, leads to 
the release of the molecule lactoferricin human (LFcinH) and lactoferricin 
bovine (LFcinB) respectively. Like LF, LFcin possesses antimicrobial activity 
against a variety of Gram-positive and Gram-negative microbes. Indeed, it is 
suggested that the molecule’s smaller size allows better access to bacterial 
membranes increasing potency (Meisel, 1998). In this respect, it can directly 
cause bacterial death complementing the iron chelating-mediated antimicrobial 
activity associated with intact LF (Jenssen & Hancock, 2009). LF has shown 
antimicrobial activity against a broad range of pathogenic bacteria, either via 
iron sequestering or direct bacterial membrane interference (García-Montoya, 
Cendón, Arévalo-Gallegos, & Rascón-Cruz, 2012). Methods for the production 
and pasteurization of both LF and LFcin have been patented and both have 
been added to a number of foods including infant formula to improve safety 
(Tomita et al., 2002). A third protein, within the LF parent sequence, 
lactoferrampin has also shown broad spectrum activity against both Gram-
positive and Gram-negative bacteria and the yeast Candida albicans. 
Lactoferrampin is found within the N1 domain of bovine lactoferrin and 
appears to be crucial for the candidacidal activity of the parent protein (Van der 
Kraan et al., 2005).  
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The αS1-casein component of casein has been shown to be a source of a 
number of AMPs. A notable and early example is isracidin, produced by the 
chymosin-mediated hydrolysis of bovine casein. The peptide possesses 
bactericidal activity against a broad range of pathogenic Gram-positive and 
Gram-negative bacteria. The Weizmann Group, the discoverers of isracidin had 
previously isolated and patented some of the earliest AMPs, the casecidins. 
Like isracidin, the casecidins had a broad spectrum of activity, particularly 
against Gram-positive bacteria (Lahov & Regelson, 1996). The casecidins 
required high concentrations in vitro in order to be effective and so were not 
seen as effective antimicrobials (Benkerroum, 2010; Lahov & Regelson, 1996). 
Similarly, isracidin also requires high concentrations in vitro (Hayes, Ross, 
Fitzgerald, Hill, & Stanton, 2006). In vivo experiments with the peptide have 
shown it to be more effective however. Isracidin was shown to be non-toxic 
and effective in preventing illness due to S. aureus infection in a range of 
animals and an effective prophylactive anti-mastitis treatment over a long 
period similar to an innate immune-response (Lahov & Regelson, 1996). The 
isracidin case highlights differences in potency of antimicrobial peptides in 
vivo and in vitro and the importance of possible indirect modes of action which 
help prevent illness in the body (Benkerroum, 2010; Kolb, 2001; Lahov & 
Regelson, 1996).  
Hayes et al. (2006) described the generation of 3 AMPs also from αS1-
casein. These peptides, namely caseicin A, B and C were generated by the 
proteolytic action of a LAB strain. Caseicin A and B share homology with 
isracidin consisting of 9 and 8 amino acid residues respectively, found within 
it. Results from in vitro assays indicated that these peptides (particularly 
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caseicin A) had potencies similar to that of isracidin against E.coli and were 
also effective against other Gram-negative bacteria but less so against Gram-
positives. Caseicin A possesses a +2 positive charge and has a lower minimum 
inhibitory concentration (MIC) value than the neutral caseicin B. Caseicin C is 
the least potent of the three described (Hayes et al., 2006). A second study by 
Hayes et al. (2009) investigated the possibility of producing a safe 
antimicrobial agent capable of inhibiting the growth of Cronobacter in infant 
formula. The study used a filtered (3kDa) lactic acid bacteria (LAB) fermentate 
derived from sodium caseinate containing both caseicin A and B peptides and 
added it to PIF at various concentrations. At 0.2% (wt/vol) the antimicrobial 
agent had a bacteriostatic effect on the pathogen and at higher concentrations, a 
bactericidal one. As the organisms and materials used in the production of this 
antimicrobial ingredient have generally regarded as safe (GRAS) status, the 
research demonstrated a viable and feasible approach to inhibit the growth of 
Cronobacter in PIF (Hayes et al., 2009).The work described in Chapters 3 and 
4 of this thesis expand on these particular peptides. Chapter 3 describes the 
generation of caseicin A and B via Bacillus-mediated hydrolysis of casein. 
Results indicated that the enzyme complement responsible for caseicin 
generation is a common feature of a number of closely related Bacillus species. 
Chapter 4 of this thesis describes the use of Bacillus derived enzymes to 
generate caseicin A. Bacillus/Bacillus enzyme generated caseicin peptides 
maintained antimicrobial activity.   
Casocidin-1 is a 39 amino acid sized fragment originating from bovine 
αS2 casein characterised in 1995 which possesses antimicrobial activity against 
a range of bacteria including Bacillus, E. coli and Staphylococcal strains 
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(Zucht, Raida, Adermann, Magert, & Forssmann, 1995). It was proposed that 
this peptide could be used in a number of food products including infant 
formula as a preservative with antibacterial properties. It has not been used 
commercially yet however due to the difficulty in producing a pure product. It 
has been proposed that a crude milk preparation containing casocidin-1 would 
be a better alternative to a pure product in order to ease production 
(Benkerroum, 2010). In fact it was reported that various fractions of a crude 
preparation possessed some antimicrobial activity suggesting a synergistic 
effect between a number of factors (Zucht et al., 1995).  
ĸ-casein has also been a source for antimicrobial bioactives, most 
notably kappacin, also known as caseinomacropeptide (CMP). CMP exists in a 
number of variations but is active only in a nonglycosyltated, phosphorylyated 
form (Malkoski et al., 2001). Kappacin was patented (Reynolds, 2009) and has 
been used commercially as an oral hygiene product in its pure form and also in 
a combination with zinc (which enhances its antibacterial activity). It has been 
proposed that kappacin could also be used as a preservative due to its broad 
antimicrobial activity and the history of safe use of ĸ-casein. Kappacin also 
possesses higher antimicrobial activity in foods with high calcium contents 
(Benkerroum, 2010). PIF has a minimum of ~50 mg/ml (CAC 2007) of 
calcium per serving which would serve to increase the potency of this 
antimicrobial peptide.  
A considerable number of peptides isolated from milk have been 
reported with various activity and possibilities to prevent the growth of 
contaminants in PIF (Benkerroum, 2010). Some may be better candidates for 
PIF supplementation than others but for all bioactive peptides there are number 
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of hurdles that must be overcome. The natural concentration of peptides in 
milk is low. Financially viable processes that lead to stable peptides which give 
reproducible results are needed. To date the commercial production of 
bioactives has been restricted due to a lack of large scale technologies. 
Following hydrolysis, milk is often filtered to concentrate the peptides and 
sometimes fractionated to produce pure peptides (H. Korhonen & Pihlanto, 
2007). As highlighted by the case of casocidin-1, lengthy and difficult 
production methods can affect the success of a product. Production difficulties 
may be offset by potent antimicrobials which can be added in minute amounts 
to batches of PIF or by generating powders containing antimicrobials that have 
not undergone the same level of processing (filtering, fractionation) and 
maintain the ability to inhibit pathogen growth (Hayes et al., 2009).  The case 
of isracidin where interest waned due to variations in results indicates the 
importance of batch stability for a successful product. Isracidin also 
demonstrates the differences between in vitro and in vivo assays when working 
with bioactive peptides as they can stimulate the immune system indirectly 
increasing efficacy in ways not yet understood (Kolb, 2001; Lahov & 
Regelson, 1996). As peptides designed to prevent the growth of pathogens such 
as Cronobacter would have served their intended purpose before ingestion, 
stability against stomach enzymes would not be an issue. Metal cations in 
certain foods can adversely affect cationic peptides though so reactivity with 
other components present in formula would be have to addressed (H. Korhonen 
& Pihlanto, 2006). Of course, any additive to PIF must be completely safe and 
not interfere with the organoleptic qualities of the food product.  
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An AMP generated from a cheap safe source like milk which meets the 
criteria would prevent the post-rehydration growth of contaminants when 
added to PIF. Keeping these bacteria at a low level could prevent illness and 
subsequent deaths and morbidities. An AMP, alone or in synergy with another 
compound may be the best method to increase the safety of PIF.  
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1.5.2. Organic Acids 
As a group, organic acids primarily include the saturated straight-chain 
monocarboxylic acids as well as their respective derivatives (phenolic, 
hydroxylic, unsaturated and multicarboxylic versions) (Cherrington, Hinton, 
Mead, & Chopra, 1991). They have a long history of use in food products as 
additives and preservatives for prevention of microbial and fungal 
contamination in food production, processing and storage (Ricke, 2003). In 
products for human consumption, acetic, sorbic, benzoic and propionic acid 
constitute the most commonly used acid preservatives due to good solubility, 
taste and their low toxicity (Cherrington et al., 1991). Although the 
mechanisms of antimicrobial activities of organic acids have yet to be fully 
elucidated they are capable of exerting a bacteriostatic or bactericidal effect. 
These effects are influenced by the physiochemical state of both the organism 
in question and the surrounding environment. pH is considered the primary 
determinant given the weak acidic nature of most of these compounds (Back, 
Jin, & Lee, 2009; Ricke, 2003). It is assumed that undissociated forms of 
organic acids can penetrate the cell membrane and once internalised into the 
neutral pH of the cytoplasm, disassociate into anions and protons effecting the 
function of macromolecules within the cell (Back et al., 2009; P. Davidson, 
Doyle, Beuchat, & Montville, 2001; Ricke, 2003). Exporting excess protons 
requires ATP and may result in a depletion of cellular energy (P. Davidson et 
al., 2001). 
Direct acidification of infant formula with lactic acid was reported to be an 
effective method to prevent the rapid growth of a number of pathogenic 
bacteria. Infant formula was first fermented with a lactic acid bacteria which 
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negatively influenced the growth of certain pathogens inoculated into the 
formula. To determine if this effect was due to pH or the presence of the 
fermenting bacteria, the authors compared the fermented formula with 
unfermented lactic acid acidified formula. They concluded that the formula 
acidified with lactic acid had similar bacteriostatic properties as the fermented 
formula (Joosten & Lardeau, 2005). Due to the increasing interest in anti-
Cronobacter strategies for infant formula there has been a recent increase in 
the number of studies investigating the potential of organic acids as protectants.  
 Recently, nine organic acids were investigated for anti-Cronobacter 
activity. Five of them, namely malic, formic, propionic and citric acid inhibited 
growth of one or more of the strains investigated on laboratory media. Agar 
disc diffusion assays showed that propionic acid was the most effective against 
the 71 strains of Cronobacter investigated, producing zones of inhibition (1.5 
cm diameter) for all strains except one. From these assays, the authors 
concluded that the order of inhibition of the organic acids they used against the 
Cronobacter strains was propionic acid > acetic acid > malic acid ≥ citric acid 
> formic acid. Further assays using the most effective acids, propionic and 
acetic in a number of food systems, including a nutrition shake designed for 
infants (PediaSure®, ARLA FOODS) showed a bacteriostatic or bactericidal 
effect at 10 mM and 100 mM, respectively. In this study, hydrochloric acid (pH 
4) did not inhibit Cronobacter in antimicrobial assays while organic acids at 
the same pH did indicating that inhibition of growth was not primarily due to 
pH (Back et al., 2009). 
In a study published in 2013, Choi et al. demonstrated that combinations 
of caprylic acid, citric acid and vanillin had a destructive effect on a number of 
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Cronobacter and S. Typhimurium. In their study, the authors spiked 
reconstituted PIF with the bacteria before adding the antimicrobial compounds. 
Results indicated that there was a significant synergistic action by the 
antimicrobials against the pathogens. The authors validated their initial 
findings by using desiccated cells in order to replicate the type of 
contamination usually seen in real-world applications. Once again, viability of 
the Cronobacter and S. Typhimurium strains was not maintained under the 
conditions examined. Flow cytometry and electron microscopy indicated 
plasmolysis and membrane disintegration led to bacterial death (Choi, Kim, 
Lee, & Rhee, 2013).   
 A recent study determined the effect of a number of organic acids on 
Cronobacter growth in both reconstituted PIF and laboratory media as well as 
the bacteriostatic effect of PIF, slightly acidified with acetic acid (pH 6.0) in 
combination with a simulated gastric model. The growth characteristics of 30 
Cronobacter strains at various pH conditions in laboratory medium was first 
investigated, the results of which indicated that the majority of strains 
investigated (86 %) were resistant to pH 5.0, with zero growth inhibition 
observed over a 24 h period. The remaining four strains that were sensitive to 
pH 5.0 were deemed acid sensitive and used in the antimicrobial assays. In 
laboratory medium acetic, butyric and propionic acids were most inhibitory. 
The strains investigated were capable of growth at pH 5.5 except when 
exposed to these acids. The inhibitory effect of these acids in laboratory media 
was not observed in reconstituted PIF alone but had a synergistic effect when 
combined with simulated infant gastric conditions as demonstrated by a 
significant delay in growth of the acid-sensitive Cronobacter strains (Acetic 
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acid used to acidify the PIF) (Zhu, Schnell, & Fischer, 2013). The benefits of 
milk acidification for infants has previously been demonstrated (Carrion & 
Egan, 1990). However, as strong acid acidification is not always well tolerated, 
interest in the use of organic acids compounds in PIF to control and inhibit the 
growth of contaminants is rising (Ricke, 2003). Previously, it has been reported 
that Cronobacter strains pre-exposed to highly acidic conditions have a higher 
tolerance against subsequent acidic exposures (Kim et al., 2012). Hence, 
directly acidifying formula to a lower pH may not be the best option in terms 
of microbial protection. Zhu et al. concluded that milder acidification of 
formula, in conjunction with infant gastric acid may achieve a protective 
function similar to direct acidification to a lower pH and will also lead to a 
product more readily accepted by the infant (Zhu et al., 2013). 
 With regards to Cronobacter, one cause for concern with infant formula 
acidification would be variation in intra-genus susceptibility to the compounds, 
which has been previously demonstrated (Back et al., 2009; Zhu et al., 2013).  
Currently propionic and acetic acids are recognized as among the most potent 
anti-Cronobacter acids (Back et al., 2009; Kim et al., 2012; Oshima et al., 
2012; Ricke, 2003; Zhu et al., 2013) possibly due to the greater proportion of 
acid molecules in an undisassociated form relative to other acids, which can 
increase levels of cytoplasmic acidification in bacteria (P. Davidson et al., 
2001).  
From a regulatory perspective, although propionic and acetic acid have 
GRAS status they are not currently included in Codex standards for infant 
formula. Organic acids such as these may have application for the improved 
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safety of PIF alone or in combination with another antimicrobials following 
further research.  
 
1.5.3. Probiotics and prebiotics 
Probiotics (‘Live microorganisms (bacteria or yeasts), which when 
ingested or locally applied in sufficient numbers confer one or more specified 
demonstrated health benefits for the host’ (FAO/WHO., 2001)) are 
increasingly being added to infant formula due to health benefits with which 
they are associated (Mugambi, Musekiwa, Lombard, Young, & Blaauw, 2012; 
Shah, 2007). Prebiotics (‘non-digestible carbohydrates which beneficially 
influence the growth of a specific group of bacteria in gastro-intestinal tract’ 
(Boehm et al., 2005)) such as Fructooligosaccharide (FOS) and Beta-galacto-
oligosaccharide (GOS) inclusion in PIF has also become commonplace due to 
the purported effect they have on the growth of beneficial bacteria (Kent & 
Doherty, 2014). Various oligosaccharides have been investigated to confirm 
their prebiotic potential, such as acidic and neutral (GOS) and from pectin 
hydrolysis, short-and long chain FOS, inulin, and combinations of these 
substances (Francescato et al., 2013). The term “Synbiotic” is used when both 
probiotics and prebiotics are administered together. Early colonization of the 
gut by commensal microorganisms is associated with a number of beneficial 
outcomes during infancy, including nutrient provision to the host via 
hydrolysis of non-digestible food components, modulation of mucosal 
immunity and the bacteria-mediated production of metabolites such as short 
chain fatty acids. Of relevance to this article is the fact that the presence of 
commensal bacteria in the gastrointestinal tract (GIT) is associated with a 
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decrease in pathogenic adherence and colonization of the gut (Zocco, Ainora, 
Gasbarrini, & Gasbarrini, 2007).  
To date, the outcomes associated with probiotic and prebiotic PIF 
supplementation are associated with improving stool frequency/consistency, 
improving gastro-intestinal comfort and reducing the incidence of allergy 
(Braegger et al., 2011; Mugambi et al., 2012). While an increase in commensal 
bacteria in the GIT may indirectly lower the risk of infection due their effect on 
pathogenic adhesion, few studies investigating a direct inhibitory effect on 
Cronobacter have been reported. In one such study strains of Lactobacillus 
acidophilus and Lactobacillus casei initially isolated from infant stool samples 
were screened for antimicrobial activity against C. sakazakii strains isolated 
from infant formula. The authors demonstrated that bacteriocin production by 
the LAB strains (demonstrated by the use of a cell-free supernatant of the cells) 
had a significant inhibitory effect on the C. sakazakii isolates in reconstituted 
PIF. Activity was not observed following heat treatment or treatment with 
gastric enzymes indicating the bacteriocins were heat labile which could make 
their inclusion in powdered milk products difficult. The inclusion of live L. 
acidophilus and L. casei strains in reconstituted PIF also had an antimicrobial 
effect on certain strains of C. sakazakii while the CFU/ml of the LAB strains 
increased by about 2 logs (over a 6 h period). The authors concluded that 
further research was required to decide the best way to incorporate either the 
antimicrobial metabolites generated by the LAB strains, or the strains 
themselves into a PIF product (Awaisheh, Al‐Nabulsi, Osaili, Ibrahim, & 
Holley, 2013).  
 38 
A number of studies have indicated that prebiotic compounds can 
influence bacterial adhesion to the GIT (Hickey, 2012; Lane, Mehra, 
Carrington, & Hickey, 2010). The ability of an oligosaccharide to block 
adhesion depends on a structural similarity between carbohydrate binding sites 
usually recognised by pathogenic bacteria and the prebiotic. The prebiotic then 
binds to adhesins on the pathogen thereby inhibiting adherence to host 
epithelial cells (Shoaf‐Sweeney & Hutkins, 2008). With specific regard to 
Cronobacter adhesion inhibition, a study by Quintero et al. found that either 
singly or in combination GOS and polydextrose (PDX) significantly reduced 
the levels of adherence in-vitro on two cell-lines representing the gut 
epithelium. Interestingly, both GOS and PDX are two oligosaccharides 
commercially used in infant formulae. It should be noted that the effects in-
vivo were not investigated and the study used levels of GOS and PDX at higher 
concentrations than that found in infant formula. 
Although initial results are promising, further studies are required to 
confirm if probiotics and/or prebiotics could effectively reduce Cronobacter 
infections related to PIF through adhesion inhibition or a direct antimicrobial 
action. Due to the current interest in Cronobacter further studies may lead to 
the discovery of GRAS strains with potent anti-Cronobacter activity. These 
strains would have to be able to survive the harsh processing and shelf-life 
conditions associated with PIF. If this inhibitory action was due to bacteriocin 
production, efficacy would have to be confirmed in-vivo as expression of 
bacteriocins by bacteria can differ from in-vitro conditions (Awaisheh et al., 
2013). Economic factors would also be an issue particularly with regard to 
prebiotic oligosaccharides. For example, even if a human milk oligosaccharide 
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was found to inhibit Cronobacter adhesion, its commercial use would be 
difficult to implement.   
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1.5.4. Alternate methods of PIF sterilization under research 
 Current knowledge dictates that total sterilization of PIF is only 
possible using irradiation, but as previously mentioned, this is forbidden by the 
Codex Alimentarius guidelines on PIF production. In PIF, Cronobacter is 
present in a dessicated state and the high doses required to inactivate it would 
have severe adverse effects on the organoleptic quality of the product (Codex 
Alimentarius Commission CAC, 2007; FAO-WHO, 2006; FAO, 2007). 
Currently the use of technologies such as magnetic fields and ultra-high 
pressure are at early stages of development and their effectiveness has not yet 
been established (Strydom et al., 2012). The use of microwave technology on 
reconstituted PIF has proven effective at reducing numbers of Cronobacter 
cells in what is believed to both a non-thermal electromagnetic radiation effect 
and a direct thermal effect on the bacteria. In one trial, microwaving 
reconstituted PIF for 90s at 93°C effectively reduced an inoculum of 100 
CFU/ml Cronobacter cells to zero (Kindle, Busse, Kampa, Meyer-König, & 
Daschner, 1996). However, the effect of this treatment on the nutrient value of 
the product would likely be an issue. There would also likely be adherence 
issues on the part of caregivers with this treatment. 
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1.6. Conclusions and Future perspectives 
 The microbiological integrity of PIF has been re-examined over the past 
decade in part due to the emergence of Cronobacter. A number of guidelines 
and regulatory changes have been published (Codex Alimentarius Commsion 
CAC, 2008; WHO, 2007) in order to aid caregivers and manufacturers of PIF 
and PIF ingredients reduce the chance of catastrophic contamination by 
pathogenic bacteria. Strict adherence to these guidelines will reduce incidences 
of PIF mediated infection (Norberg et al., 2012). However, it is likely that on 
certain occasions these recommendations will not be followed either through 
negligence or incompetence. When this occurs the inclusion of antimicrobial 
solutions may help prevent illness. Natural antimicrobials, in particular those 
with GRAS status are of interest due to consumer concerns regarding chemical 
additives. 
 With specific regard to Cronobacter, a significant challenge is the 
identification of specific virulence factors related to particular species or strains 
(Strydom et al., 2012). However, the recent increase in research on this genus 
has led to greatly improved detection methods and knowledge of important 
characteristics of individual species. Molecular methods are increasingly used 
to reliably and rapidly trace sources of infection and to study diversity between 
bacterial genomes (Holý & Forsythe, 2014). Increasingly, Multilocus sequence 
typing (MLST) is used to understand the diversity and evolution of pathogenic 
bacteria. A MLST scheme for Cronobacter (Jolley & Maiden, 2010) is 
available online (http://pubmlst.org/cronobacter/) and currently contains ~900 
isolates. Researchers group sequence types elucidated by MLST into clonal 
complexes decided by similarities to a central allelic profile. The C. sakazakii 
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clonal complex ST4 has been frequently isolated from PIF processing plants, 
milk powder processing facilities and PIF itself (Holý & Forsythe, 2014; 
Joseph & Forsythe, 2011; Müller et al., 2013; Power, Yan, Fox, Cooney, & 
Fanning, 2013) and is associated with cases of meningitis. Control of the ST4 
lineage could reduce infant exposure to particularly virulent strains (Holý & 
Forsythe, 2014). Information derived from the study of strains from this clonal 
complex may also allow researchers to develop specific methods to prevent 
growth of virulent strains in various environments. 
 A multi-directional approach may be the most effective. For PIF 
producers, continued research into effective decontamination methods coupled 
with improved training and education of staff and strict implementation of 
good manufacturing principles are required. Efforts to educate medical staff 
and infant caregivers regarding proper handling and storage of the product 
should be increased (Strydom et al., 2012). Consumers should also receive 
clear and accurate information regarding the risk of infection associated with 
various formulae so that they may make informed decisions regarding how to 
feed the infant (Jason, 2012). Finally, the inclusion of antimicrobials either 
singly, or in synergy with another compound or process will lower incidences 
of infection.    
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Table 1.1. 
Nutrient Minimum Maximum 
Protein (g) 1.8 3 
Taurine (mg)   12 
Lipids (g) 4.4 6 
Linoleic acid (mg) 300 1200 
Phospholipids (g)   2 
Carbohydrates (g) 9 14 
Lactose (g) 4.5   
Sucrose *   >20 % 
Glucose (g) *   2 
Pre-cooked/gelatinised starch   30 % of total carb content 
FOS/GOS **   0.8 g/100 ml 
Sodium (mg) 20 60 
Potassium (mg) 60 160 
Chloride (mg) 50 160 
Calcium (mg) 50 140 
Phosphorous (mg) 25 90 
Magnesium (mg) 5 15 
Iron (mg) 0.3 1.3 
Zinc (mg) 0.5 1.5 
Copper (µg) 35 100 
Iodine (µg) 10 50 
Selenium (µg) 1 9 
Manganese (µg) 1 100 
Fluoride (µg)   100 
Vit A (µg-RE) 60 180 
Vit D (µg)  1 2.5 
Vit K (µg) 4 25 
Vit E (mg α-TE) *** 5 
Vit C (ascorbic acid) (mg) 10 30 
Vit B1 (thiamine) (µg) 60 300 
Vit B2 (riboflavin) (µg) 80 400 
Vit B6 (pyroxidine) (µg) 35 175 
Vit B12 (µg) 0.1 0.5 
Niacin (µg) 300 1500 
Folic Acid (µg) 10 50 
Pantothenic acid (µg) 400 2000 
Biotin (µg) 1.5 7.5 
Choline (mg) 7 50 
Inositol (mg) 1 10 
cytidine 5´-monophosphate (mg)   2.5 
uridine 5´-monophosphate (mg)   1.75 
adenosine 5´-monophosphate (mg)   1.5 
guanosine 5´-monophosphate (mg)   0.5 
inosine 5´-monophosphate (mg)   1 
* only allowed in protein hydrolysate 
** shall not exceed 90 % oligogalactoysyl-lactose and 10 % high molecular weight 
oligofructosyl-saccharose 
*** 0.5 g of polyunsaturated fatty acids expressed as linoleic acid as corrected for the 
double bonds but in no case less than 0.5 mg per 100 available kcal  
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2.1. Abstract 
Genetic diversity and genomic rearrangements are a driving force in 
bacterial evolution and niche adaptation.  We sequenced and annotated the 
genome of Lactobacillus johnsonii DPC6026, a strain isolated from the porcine 
intestinal tract.  Although the genome of DPC6026 is similar in size (1.97mbp) 
and GC content (34.8%) to the sequenced human isolate L. johnsonii NCC 533, 
a large symmetrical inversion of approximately 750kb differentiated the two 
strains. Comparative analysis among 12 other strains of L. johnsonii including 
8 porcine, 3 human and 1 poultry isolate indicated that the genome architecture 
found in DPC6026 is more common within the species than that of NCC 533. 
Furthermore a number of unique features were annotated in DPC6026, some of 
which are likely to have been acquired by horizontal gene transfer (HGT) and 
contribute to protection against phage infection.  A putative type III restriction-
modification system was identified, as were novel Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) elements.  Interestingly, 
these particular elements are not widely distributed among L. johnsonii strains. 
Taken together these data suggest intra-species genomic rearrangements and 
significant genetic diversity within the L. johnsonii species and indicate 
towards a host-specific divergence of L. johnsonii strains with respect to 
genome inversion and phage exposure. 
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2.2. Introduction 
The Gastro-intestinal (GI) tract is colonized by a vast and diverse 
community of microbes.  Lactobacilli represent an important part of the natural 
gut microbiome of both humans and animals and have been extensively studied 
for their health promoting properties.  Lactobacillus johnsonii is a member of 
the closely related “acidophilus complex” of lactobacilli and an autochthonous 
species of the gastro-intestinal tract.  L. johnsonii strains are of interest due to 
the number of probiotic characteristics associated with this species, including 
immunomodulation, (Haller et al., 2000; Ibnou-Zekri, Blum, Schiffrin, & von 
der Weid, 2003; Inoue, Otsuka, Nishio, & Ushida, 2007; Kaburagi et al., 2007) 
attachment to epithelial cells (Granato et al., 2004; Neeser et al., 2000) and 
pathogen exclusion (Bernet, Brassart, Neeser, & Servin, 1994; La Ragione, 
Narbad, Gasson, & Woodward, 2004; Wegmann et al., 2009).  
For organisms commonly found in GI tract such Lactobacillus 
acidophilus, Lactobacillus gasseri and L. johnsonii there are a number of 
genome sequences available which have identified genetic traits that most 
likely function in gastric survival and promote interactions with the intestinal 
mucosa (E. Altermann et al., 2005; Azcarate-Peril et al., 2008; Pridmore et al., 
2004; Wegmann et al., 2009).  It has been proposed that GI-associated strains 
have adapted to their niche with a specialized set of metabolic and surface-
related proteins (O'Sullivan et al., 2009). In the L. johnsonii NCC 533 genome 
for example, large cell surface proteins were identified thought to be involved 
glycoprotein adhesion and persistence in the intestinal tract (Emmanuel Denou 
et al., 2008; Pridmore et al., 2004). A common trait documented also for this 
group of organisms is a general lack of genes encoding biosynthetic pathways 
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for amino acids, purine nucleotides and cofactors which may be reflective of 
their “symbiont” nature and an abundance of ABC transporters, peptidases and 
phosphotransferases (E. Altermann et al., 2005; Azcarate-Peril et al., 2008; 
Pridmore et al., 2004).   
 Genomic heterogeneity within a bacterial species can be driven by the 
selective pressure of different environmental niches and can result from 
recombination events and the presence of mobile genetic elements (MGE), 
such as bacteriophage and IS elements.  Genetic diversity and horizontal gene 
transfer (HGT) among closely related gut lactobacilli has been observed 
(Azcarate-Peril et al., 2008; Berger et al., 2007; Canchaya, Claesson, 
Fitzgerald, van Sinderen, & O'Toole, 2006; Pridmore et al., 2004).  Within the 
‘acidophilus complex’ previous polyphasic analysis and comparative genomic 
analysis has indicated significant inter and intra-species diversity among MGE 
and at the region around the terminus of replication (Berger et al., 2007).  The 
possibility of genomic rearrangements at this region within L. johnsonii strains 
has also been previously suggested (E. Denou et al., 2008) (Contribution by 
Pridmore D; (Klaenhammer et al., 2002)).  
Here we present the whole genome sequence of the porcine L. johnsonii 
isolate DPC6026 (previously named L. acidophilus DPC6026; (Hayes, Ross, 
Fitzgerald, Hill, & Stanton, 2006)) and explore the genetic content, the 
potential genomic rearrangements and diversity within the L. johnsonii species. 
This study also presents a number of MGEs novel to the L. johnsonii species 
and previously unidentified phage resistance mechanisms. 
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2.3. Materials and Methods 
2.3.1. Bacterial strains, growth conditions   
L. johnsonii DPC6026 was originally isolated from a porcine small 
intestine (Hayes et al., 2006). This strain was previously identified as L. 
acidophilus DPC6026 however more refined 16S sequencing demonstrated that 
it belongs to the L. johnsonii species rather than the closely related L. 
acidophilus.  All isolates used in this study are outlined in Table 2.1.  Cultures 
isolated from faecal samples were as previously described (Casey et al., 2007) 
and screened on Lactobacilli selective agar (LBS).  L. johnsonii strains were 
cultured anaerobically in MRS (Difco) media at 37ºC.   
 
2.3.2. Speciation of isolates 
 DNA was extracted from 10ml overnight cultures using the procedure 
previously described (Hoffman & Winston, 1987).  The 16S rDNA were 
amplified from gDNA from each strain using species specific primers for L. 
johnsonii, L. gasseri and L. acidophilus as previously described (Walter et al., 
2000).  Chosen isolates were confirmed by amplification using 16S Eubacterial 
primers (Takai & Horikoshi, 2000) and the 16S region was sequenced by 
conventional Sanger sequencing.  The species was determined by nucleotide 
alignments (>98%) with deposited species in the NCBI database. Strains of the 
same species were confirmed to be different isolates by Pulsed-Field-Gel-
Electrophoresis using the apaI enzyme (not shown). 
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2.3.3. Phylogenetic analysis 
Reconstruction of evolutionary relationships were carried out using the 
MEGA 4 package (Tamura, Dudley, Nei, & Kumar, 2007).  16S rRNA 
sequence data was obtained from GenBank (L. johnsonii AE017198, L. gasseri 
CP000413, L. acidophilus CP000033, Lactobacillus sakei CR936503, 
Lactobacillus reuteri CP000705, Lactobacillus fermentum AP008937, 
Lactobacillus brevis HQ622718, Lactobacillus plantarum CP002222, 
Lactobacillus salivarius CP000233 and Lactobacillus casei FM177140) and 
was used to construct a consensus neighbour joining tree from 500 
bootstrapping replicates.   
 
2.3.4. Genome sequencing, assembly and comparative genomic analysis 
 Massively parallel 454 pyrosequencing with paired end tags of 
DPC6026 to a coverage of 23X was performed by 454 Beckmann Coulter 
Genomics (www.beckmancoulter.com) on a FLX sequencer followed by initial 
assembly in to 83 contigs using the Newbler program (roche-applied-
science.com).  Order and orientation of assembled contigs and predicted 
scaffolds was determined using the published genome sequences of L. 
johnsonii NCC533 (Pridmore et al., 2004) and L. johnsonii FI9785 (Wegmann 
et al., 2009).  Primers were designed at gap edges using primer3 (Rozen & 
Skaletsky, 2000) for PCR amplification of gap regions using Platinum Hi-
fidelity PCR Supermix (Invitrogen) or Kod DNA Polymerase (Novagen).  
Reactions were performed in a Biometra TGradient followed by directed 
sequencing of PCR products by primer walking, and whole genome assembly 
was performed using the PHRED-PHRAP-CONSED package (Ewing & Green, 
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1998; Gordon, 2003). Raw assembly reads were visualised and verified using 
the programme Hawkeye (Amos) (Schatz, Phillippy, Shneiderman, & Salzberg, 
2007). Unmapped contigs were mapped using combinatorial PCR followed by 
primer walking.  Frameshifts and ribosomal operons were annotated but not 
verified by conventional Sanger sequencing. 
Coding regions were predicted using Glimmer 2 (Delcher, Harmon, 
Kasif, White, & Salzberg, 1999) and annotation was performed using 
GAMOLA (Eric Altermann & Klaenhammer, 2003). Complementary 
annotation data were provided by the SEED (Overbeek et al., 2005) and the 
RAST annotation server (Aziz et al., 2008).  Data was manually curated (Oct 
2010) using Artemis software V11 (Tim Carver et al., 2008) where additional 
programmes were used including, PROSITE (www.expasy.ch) RBS finder 
(Delcher et al., 1999) and GATU (Tcherepanov, Ehlers, & Upton, 2006). 
Comparative genomics was performed using the Artemis comparison tool (T. J. 
Carver et al., 2005; Darling, Treangen, Messeguer, & Perna, 2007) and 
MAUVE software (Darling et al., 2007).  Circular maps were created using 
DNA plotter (T. Carver, Thomson, Bleasby, Berriman, & Parkhill, 2009).   
 
2.3.4. Detection of novel features of DPC6026 
  Primers specific to the regions of genomic rearrangements were 
designed based on the genome sequences of DPC6026 and NCC533 (Table 
2.2).  Primers specific to 4 regions of the integrated prophage and the site of 
prophage integration were designed based on DPC6026.  The primers used to 
detect the CRISPR elements and restriction modification systems were 
designed based on DPC6026 with at least 2 different specific combination of 
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primers used (Table 2.2).  PCRs were performed on all strains (Table 2.1) to 
confirm genomic structure and elements using either Platinum Hi-fidelity PCR 
Supermix (Invitrogen) or Biotaq (Bioline). 
 
2.3.5. Phage Induction 
The induction of the prophage Фlj6026 was attempted by heat where the 
culture containing the phage was subjected to a thermal stress of 42°C for 1 
hour or following the addition of mitomycin C (2-6µg/ml) (Sigma Chemical 
Co., St. Louis, MO).  L.  johnsonii was grown overnight in MRS broth at 37°C 
anaerobically.  Fresh broth was inoculated with a 1% inoculum of the 
overnight strain and grown to OD600nm 0.1-0.3. The culture was centrifuged 
and the supernatant was filtered through a 0.45µm filter. The filtered 
supernatant was spotted on an overlay of a range of indicator strains and 
prophage release was determined by observing zones of lysis following 
incubation at 37ºC for 24h (Table 2.1).  
 
2.3.6. Public data sources 
The genome sequence of L. johnsonii DPC6026 is available from 
GenBank/EMBL under the accession number CP002464. 
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2.4. Results 
2.4.1. General features of the genome of L. johnsonii DPC6026 
 The DPC6026 genome consists of a singular circular chromosome of 1.97mbp 
with an average G+C content of 34.8% and does not harbour any plasmids 
(Figure 2.1.).  Overall, the genome of DPC6026 was highly similar to the 
previously sequenced members of the species L. johnsonii in size, G+C content 
and gene synteny (Pridmore et al., 2004; Wegmann et al., 2009). Total GC-
skew analysis and the ORF orientation drift identified the oriC proximal to 
dnaA and the terC at ~1.05mb (Figure 2.1.).  In silico analysis predicted 1795 
protein coding genes.   
Phylogenetic analysis based on the 16S rRNA gene sequences of L. 
johnsonii and other Lactobacilli revealed, in accordance with previous work 
(Zhang, Ye, Yu, & Shi), that L. johnsonii is closely related to other L. 
acidophilus complex members (Figure 2.2.). It is most related however to the 
gut bacterium L. gasseri as they occupy the same branch on the phylogenetic 
tree (Figure 2.2.).   
 
2.4.2. Genetic homogeneity of the core genome of L. johnsonii sequenced 
isolates 
Among the genes encoded in DPC6026, 150 genes (~9%) were not found in 
the human isolate NCC 533 (Pridmore et al., 2004), 84 genes (5%) were novel 
to the L. johnsonii species and just 18 (1%) genes were not previously 
identified in the genus Lactobacillus.  These results are in accordance with 
previous work by Berger et al., (2007) which indicated a conservation of genes 
between L. johnsonii isolates to be between 83-92% with 5% strain specific 
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genes (Berger et al., 2007).  Genes novel to DPC6026 largely represented 
mobile DNA including genes encoding proteins with homology to phage 
related proteins, transposase and insertion elements.   
The metabolic capabilities and biosynthetic pathways of DPC6026 are 
in accordance with the reliance of L. johnsonii on the surrounding environment 
for nutrients (Pridmore et al., 2004).  DPC6026 has a high number of PTS 
systems and ABC transporters enabling utilization of sugars available in the GI 
tract, similar to the closely related genomes of the ‘acidophilus complex’ (E. 
Altermann et al., 2005; Azcarate-Peril et al., 2008; Pridmore et al., 2004).  
There were also 20 proteins with homology to peptidases annotated in the 
DPC6026 genome, including eight aminopeptidases, six dipeptidases and three 
endopeptidases.  This is in agreement with the dependency of the L. johnsonii 
on exogenous amino acids for growth.  The extracellular cell wall bound 
proteinase (LJ1840) that was annotated in NCC533 however was not found in 
the porcine strain.  PCR analysis indicated that this was not present in any of 
the porcine isolates tested (not shown).   This was surprising as the L. johnsonii 
DPC6026 strain was previously indicated to have proteolytic ability (Hayes et 
al., 2006) and it was reported that DPC6026 generates antimicrobial peptides 
from casein in milk-based fermentations (Hayes et al., 2006).  However, our 
phenotypic analysis supports the genomic prediction that this strain alone 
cannot hydrolyse milk efficiently and further analysis to the possibility of 
indigenous microbiota from the fermentation substrates contributing to 
proteolysis and the liberation the antimicrobial peptides is ongoing.  
The abundance of transport and regulatory proteins is also reflected in 
the genomes of L. johnsonii NCC533 (Pridmore et al., 2004) and FI9785 
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(Wegmann et al., 2009), however, there were differences in the genetic content 
of these proteins within each of the three genomes.  These differences may be 
due to a differing GI environment among the disparate host species.   Of note 
also is the differing complement of adhesion and cell surface proteins present 
in DPC6026 and in NCC533.  Pridmore et al., (2004) identified cell surface 
components (LJ0382, LJ0391, LJ1128, LJ1711, LJ1839) in the human isolate 
thought to be unique to NCC 533 and predicted to be secreted and attached to 
the cell surface. These proteins were all either absent or appeared to be 
fragmented (LJP0353, LJP0366, LJP0707 and LJP1463) in the porcine isolate. 
This could further indicate the importance of these proteins in colonisation of a 
human host.  
 
2.4.3. Genome Architecture and Synteny 
Despite a relatively conserved gene synteny between the sequenced L. 
johnsonii isolates, there is a large (~750kb) symmetrical inversion across the 
replication axis between the human isolate NCC 533 and the porcine isolate 
DPC6026 (Figure 2.3.).  Whole genome alignments also indicate that the 
porcine isolate DPC6026 and poultry strain FI9785 share the same genomic 
arrangement (not shown).  
Despite the large genomic inversion, the ori and ter regions do not 
appear to be disrupted based on the location of the inversion and on the GC-
skew data. Indeed, while a slightly imbalanced replichore is evident, there is 
not a significant change in the replichore sizes of the two strains (Figure 2.1.).  
The existence of the inversion also did not lead to a significant difference in the 
growth rate of the strains (not shown). The inversion between DPC6026 and 
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NCC 533 was confirmed by site-specific PCR.   Two primer pair sets were 
designed that overlap the left and right junction sites in DPC6026 and yield an 
amplicon in this strain but should not in NCC533 if this region had undergone 
an inversion.  When the 2 primer sets are used in the combination (F/F) and 
(R/R), a PCR product is generated in NCC533 but not in DPC6026, thus 
confirming the differing genomic structures and an inversion event (Figure 
2.6.). The genomic structure of 8 further porcine isolates and 2 human isolates 
of L. johnsonii was investigated using these primer sets.  Results indicate all 
the porcine isolates harboured the same genomic structure as DPC6026.  One 
human isolate, a type strain ATCC12088, harboured the same genomic 
arrangement as NCC533 (Figure 2.4.).  The second human/type strain tested 
did not give a PCR product for either structure.   
  At both the right and left junction sites in NCC 533 a 1,460bp sequence 
of inverted repeats was identified including an insertion element ISLjo2 of the 
ISL3 family which may be responsible for the inversion event in NCC 533 or 
in an ancestral strain (Figure 2.6.). It has been documented that recombination 
involving direct repeats can lead to genomic inversions (Achaz, Coissac, 
Netter, & Rocha, 2003) and has been suggested previously as a possibility for 
the NCC 533 strain [18].  Differing genomic structures are also apparent on 
alignments of L. johnsonii strains with the closely related L. gasseri (Figure 
2.2)   (Azcarate-Peril et al., 2008; Kaburagi et al., 2007) indicating 
rearrangements in this group of bacteria can occur frequently and ‘X-shaped’ 
inversions across the replication terminus between species of the acidophilus 
group have been documented (Berger et al., 2007).   
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 Based on the comparative genomic PCR assays it is likely that the 
structure of DPC6026 is the more commonly found genomic structure of L. 
johnsonii.  The repeat region and IS element present in NCC 533 was not 
present at this location in DPC6026 but was however at 4 other locations 
within the porcine genome.  Given that this is a common element in L. 
johnsonii genomes it may be an indication of significant genome plasticity 
within the species.  
 
2.4.4. Novel Mobile Genetic Elements of L. johnsonii  
Acquisition of genes by HGT is considered a major driving force in 
bacterial evolution and can impact on genomic structure and stability.  
Laterally acquired DNA provides a readily available pool of genes for 
developing physiological properties that are helpful in a particular niche.  A 
number of previously unidentified MGEs were identified in the DPC6026 
genome (Figure 2.5a., 2.5b. and 2.5c.). 
(i) Integrated prophage Prophages of L. johnsonii have been previously 
characterised (Ventura, Canchaya, Pridmore, Berger, & Brussow, 2003; 
Ventura, Canchaya, Pridmore, & Brussow, 2004) and are indicated to have 
large role in the diversification within the species (Canchaya, Fournous, & 
Brussow, 2004; E. Denou et al., 2008).  Genomic analyses revealed the 
presence of one complete prophage sequence, Фlj6026 (LJP0764-LJP0819), 
which is integrated next to tRNA loci at ~900kbp within the DPC6026 
genome.  Of note this prophage is within the region that is inverted relative to 
the human isolate, however is integrated in the opposite orientation (Figure 
2.3.). 
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Фlj6026 is 43,608bp in length and encodes 58 proteins comprising the 
typical phage regions of integration, replication, packaging, structural and lysis 
domains (Figure 2a.).  Фlj6026 phage shares an integration site with the 
NCC533 phage Фlj928 but most nucleotide identity with the NCC533 phage 
Фlj965 (Ventura et al., 2004).   We attempted to induce Фlj6026 by mitomycin 
C and heat treatments using the closely related L. johnsonii, L. acidophilus and 
L. gasseri strains as indicator organisms.  Release of the prophage was not 
detected by the methods used. The apparent non-functionality of lj6026 is in 
accordance with previous work that has indicated that the related prophages 
Фlj965 and Фlj928 are not inducible (Ventura et al., 2004).  Distribution of 
Фlj6026 was investigated among L. johnsonii strains and strains of the closely 
related species L. gasseri and L. acidophilus (Figure 2.4.).  Of the isolates 
tested only the porcine L. johnsonii isolate DPC6092, in addition to DPC6026, 
appeared to harbour the full phage.  Partial matches were obtained with the 
human type strain DSM10533.  Based on in silico analysis, the poultry isolate, 
FI9785 was found to also have a similar but not identical phage within the 
genome (Figure 2.4.).    
(ii) IS Elements IS elements are recognisable by DNA recombination 
machinery and can play a large role in chromosomal rearrangements. The 
annotation of DPC6026 identified 51 gene features with similarity to either 
characterized or predicted transposases or to putatively truncated or degenerate 
transposase enzymes.  The type of IS elements differed considerably among the 
L. johnsonii sequenced isolates. In DPC6026, insertion elements of the family 
IS1223 that had been identified in NCC 533 and FI9785 were found in addition 
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to copies of IS605 of in L. acidophilus NCFM (E. Altermann et al., 2005) and 
ISLhe1 of L. helveticus DPC4571 (Callanan et al., 2008).    
(iii) Restriction Modification System Restriction Modification (RM) systems 
function to cleave foreign DNA and are the most
 
common systems used to 
degrade incoming phage DNA.  A novel restriction modification system was 
annotated on the genome of DPC6026.  It is located at ~1.57mbp and consists 
of a restriction (LJP1436) and a methylase (LJP1437) component typical of the 
type III family of RM systems (Figure 2.5b.).  This type III system has not 
been previously identified in L. johnsonii and, although it does share amino 
acid identity with the restriction component of L. gasseri (90%) (Azcarate-Peril 
et al., 2008) and the modification component of Lactobacillus fermentum 
(55%) (Morita et al., 2008), the complete system does not have a close 
homolog in any sequenced LAB.  The type III R/M system is located in a 
~15kb region that is absent from NCC533 (Figure 2.5b.).  This region also 
contains a protein (LJP1446) with identity (30% amino acid) to abortive phage 
resistance proteins which suggest a combination of different phage defence 
mechanisms present.  Comparative genomic analysis indicated that this 
element is not widely distributed as it was not found in any of the other strains 
tested in this study (Figure 2.4.).   
   
2.4.5. Analysis of the CRISPR locus in DPC6026 
Clustered regularly interspaced short palindromic repeats (CRISPR) 
represent a family of DNA repeats shown to provide acquired immunity 
against foreign genetic elements (Barrangou et al., 2007; Horvath & 
Barrangou). A novel CRISPR-cas system of 6.1kb was identified in the 
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genome of the porcine isolate.  This element is positioned at the centre of the 
region that is inverted relative to NCC 533.  A slight alteration in GC content 
compared to the surrounding region suggests that this element was transferred 
by horizontal gene transfer (Figure 2.3c.).   
CRISPR systems have been  identified in nine Lactobacillus genomes 
to date (Horvath et al., 2009), including closely related members of the 
acidophilus complex, L. acidophilus (E. Altermann et al., 2005) and L. 
helveticus (Callanan et al., 2008).  Despite this, the content of the CRISPR loci 
(LJP1108-1110) in L. johnsonii was not identical when compared to elements 
in closely related organisms. Differences within the repeat region and in the 
CRISPR associated (Cas) proteins were also observed. The 36bp repeat 
5`ATCTAAACCTTATTGATCTAACAACCATCTAAAAC3` is present 28 times with 
27 unique spacer sequences.  The three genes upstream of the repeats encode 
homologues for Cas proteins which are invariably associated with CRISPR 
repeats (Figure 2c.).  This system does share some similarities with CRISPR 
loci in L. salivarius UCC118 (Claesson et al., 2006) and Lactobacillus casei 
ATCC 334 (Cai, Thompson, Budinich, Broadbent, & Steele, 2009).  Upstream 
of the first cas gene, remnant CRISPR repeats were also identified.  This 
phenomenon has previously been reported in Streptococcus thermophilus 
(Horvath et al., 2008) and Bifidobacterium animalis (Barrangou et al., 2009) 
and Bifidobacterium adolescentis (Horvath et al., 2009). The distribution of the 
element in other L. johnsonii strains was investigated and it was indicated by 
PCR analysis that only the L. johnsonii porcine isolates DPC6092 and 
DPC6214 contained a similar element indicating these elements may not be 
widespread in L. johnsonii strains (Figure 2.4.).    
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2.5. Discussion 
  The GI tract is a complex environment that provides a variety of 
ecological challenges.  The significant differences presented in this study 
highlight strain specificity among the species of the gut.  Importantly based on 
genomic structure analysis it is suggested that the human strain of L. johnsonii 
diverged from both animal and poultry isolates at some time, however, more 
representative strains of each species would need to be sequenced to shed more 
light on this.   
The chromosomal inversion, a characteristic ‘X-shaped’ symmetrical 
rearrangement in this study occurs within strains of the same species and based 
on previous analysis on closely related species it would seem that inversions 
across the replication axis occurs frequently in this group of Lactobacilli during 
evolution (Berger et al., 2007; Canchaya et al., 2006).  Large genomic 
inversions are generally not common among bacteria of the same species but 
have been described in a number of pathogens such as E. coli (Kotewicz, 
Jackson, LeClerc, & Cebula, 2007), Salmonella sp. (Liu & Sanderson, 1996), 
Yersinia pestis (Deng et al., 2002), Staphylococcus aureus (Shukla, Kislow, 
Briska, Henkhaus, & Dykes, 2009) and also in the non-pathogenic Lactococcus 
lactis (Daveran-Mingot, Campo, Ritzenthaler, & Le Bourgeois, 1998).  It has 
been indicated that inversions may not necessarily have a selective advantage 
or disadvantage or dramatic phenotypic effect (Daveran-Mingot et al., 1998), 
however rearrangements have also been shown to have an effect on phenotype 
and cell fitness (Hill & Gray, 1988). Although both strains NCC 533 (Cai et 
al., 2009) and DPC6026 (Figure 2.1.) appear to have a slightly unbalanced 
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replichore, it does not appear to have had a detrimental effect on the growth of 
the strains (not shown). 
 Despite the relative genetic homogeneity among the core regions of the 
sequenced L. johnsonii and the gene content reflecting a similar metabolic 
lifestyle in the GI tract, there are significant differences among adhesion 
proteins, mobile genetic elements and cell protection mechanisms.  Notably, 
large differences between L. johnsonii isolates are in the phage complement 
and in putative phage resistance mechanisms. Phage integration within a 
replichore may influence genome stability leading to chromosomal inversions 
between highly conserved regions (Nakagawa et al., 2003).  L. johnsonii 
phages Фlj965, Фlj928 (Ventura et al., 2003; Ventura et al., 2004) and Фlj771 
(E. Denou et al., 2008) have been characterised and have been shown to 
contribute to strain diversity within the species (E. Denou et al., 2008). 
Фlj6026 presented in this study is integrated within the region inverted to 
NCC533 and although it shares most homology with Фlj965 they are not 
integrated at the same site in the chromosome suggesting the phage was taken 
up separately by the strains and therefore it may have a particular advantage to 
the cell.  However the functionality of this phage was not confirmed in this 
study. The existence of unique phage resistance mechanisms indicate that the 
DPC6026 genome may preferentially defend against foreign DNA integration 
using the CRISPR loci and/or the type III restriction modification system.  As 
the particular elements were not found in many of the other strains tested, 
strain specific mechanisms for phage defence appear to be present.   
It has been documented that the flora of the gut is thought to be largely 
modulated by the selective pressure imposed by the host and the other 
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microbiota present (Ley, Peterson, & Gordon, 2006). As a commensal of the 
GI tract, L. johnsonii appears to be a versatile and changing bacterium that can 
perhaps adapts to its niche by acquiring mobile genetic elements and through 
chromosomal recombination events.   
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Table 2.1.   Strains used in this study. 
Strain Species Source Reference 
a
DPC6026 L. johnsonii Porcine  (Hayes et al., 2006) 
DPC6092 L. johnsonii Porcine  (Hayes et al., 2006) 
DPC6214 L. johnsonii Porcine  (Hayes et al., 2006) 
DPC6560   L. johnsonii Porcine This study 
DPC6561  L. johnsonii Porcine This study 
DPC6562  L. johnsonii Porcine This study 
DPC6563  L. johnsonii Porcine This study 
DPC6564  L. johnsonii Porcine This study 
DPC6565  L. johnsonii Porcine This study 
NCC533  L. johnsonii Human (Pridmore et al. 2004) 
DSM10533 L. johnsonii Human /Type strain  
b
DSM  
ATCC120883 L. johnsonii Human/Type strain  
c
ATCC 
LMG9433 L. acidophilus Type strain  
d
LMG 
ATCC4356 L. acidophilus Human/Type strain  
c
ATCC 
DPC6489 L. gasseri Human  (O'Shea et al., 2009) 
LMG9203 L. gasseri Type strain  
d
LMG 
 
a
DPC collection; Dairy Product Collection, Moorepark Food Research Centre, 
Fermoy, Co. Cork. 
b 
DSM; DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen 
c 
ATCC; American Type Culture Collection
 
d 
LMG; BCCM/LMG Bacteria collection
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Table 2.2.  DPC6026 specific primers used in this study 
Region  Primer   Sequence 5’-3’ 
6026 genomic structure InversionF1   
InversionR1 
InversionF2 
InversionR2 
tatattttgggggcagttgg 
atgcttgcaaacaccaatga 
tcttgaactccacccgaatc 
tgcagaatgggttgcattta 
Фlj6026-specific  IntegraseF 
IntegraseR 
tRNA_F 
tRNA_R 
Lysin F 
Lysin R 
LJxxxF 
LJxxR 
taggttttacattagtttccg 
tggtggcagtgacaagagaa 
cctaccttaaactgtaaagca 
ctaaagttccacagtaaccac 
tttatgggttgccgcttatc 
gttccccacgggatatttct 
tccagagccgtggctactat 
gaagcgacgaggcaaattac 
 
Фlj6026-att_site attL_F 
attL_R 
attR_F 
attR_R   
   
ggccttagaaaatccgaagc 
tggtggcagtgacaagagaa 
cgcccgattaatttgagaaa 
tttttgacaagtttatgatgcaa 
 
CRISPR_system Cas1_F 
Cas1_R 
Cas2_F 
Cas2_R 
Csn1_F 
Csn1_R 
ggtctgtgataataacacagc 
tcattcggtacctcatgaattagc 
gctatggtatgcagataatcgc 
cagtaccaatcaacaaggtcctgat 
gtactgattcatgtggatgggtag 
tgcattttctgagagtattacgcc 
RM system Res_F 
Res_R 
Mod_F 
Mod_R 
ttggcttgctcaacactttg 
ttgtttggcttccacaatca 
gaagcaatgcagagcgtaaa 
taagctgcatcacagcatcc 
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Figure 2.1. Genome Atlas of L. johnsonii DPC6026  The tracks from the 
outside represent 1. Forward CDS, 2. Reverse CDS, 3. Misc.features/MGE, 4. 
tRNA, rRNA   5.  % GC plot 6. GC skew. 
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Figure 2.2. Phylogenetic tree based on the 16S rRNA gene sequences of 
Lactobacillus species 
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Figure 2.3. Pairwise comparison of the chromosomes L. johnsonii 
DPC6026 and NCC533 using ACT. The sequences have been aligned from 
the predicted replication origins (oriC). The colored bars separating each 
genome (red and blue) represent similarity matches identified by BlastN 
analysis, with a filter cutoff of 100. Red lines link matches in the same 
orientation; blue lines link matches in the reverse orientation.   
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Figure 2.4. Comparative genomics of Lactobacillus strains. The distribution 
of the genomic inversion, the CRISPR loci, the type III restriction modification 
system and the integrated prophage among a panel of L. johnsonii isolates of 
human (red), poultry (blue) and porcine (green) origin, L. gasseri and L. 
acidophilus strains.  A filled square indicates presence of the element, a 
hatched square indicates a partial element and an empty square indicates the 
element in absent. 
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(a) 
 
(b) 
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 (c) 
 
 
Figure 2.5. Graphic representation of the phage Фlj6026 and its 
demonstrated functionality (a), the graphical representation of the 
restriction modification (RM) system (b) and the CRISPR loci (c) in the 
genome of DPC6026.  Genes within a mobile element that are annotated to 
have a similar function are coloured the same. The CRISPR (csn) gene is 
represented by dark orange arrow and CRISPR-associated genes (cas1, cas2) 
are represented by light orange arrows.  Repeat/spacer region (36 DR; Direct 
Repeats) are represented by brown lines.  The entire CRISPR associated region 
is represented by a filled grey rectangle corresponding to the lowered GC 
content as predicted by Artemis 
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Fig 2.6. Schematic diagram of the genetic elements at the left and right 
junction sites in NCC533 with reference to DPC6026.  In both junction sites, 
a transposase with an IS element (hatched box) and 140bp conserved sequence 
(filled grey box). 
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3.1. Abstract 
Aims: The aim of this study was to identify Bacillus isolates capable of 
degrading sodium caseinate and subsequently to generate bioactive peptides 
with antimicrobial activity. 
Methods and results: Sodium caseinate (2.5% w/v) was inoculated separately 
with 16 Bacillus isolates and allowed to ferment overnight. Protein breakdown 
in the fermentates was analysed using gel permeation-HPLC (GP-HPLC) and 
screened for peptides (<3-kDa) with MALDI-TOF mass spectrometry. 
Caseicin A (IKHQGLPQE) and caseicin B (VLNENLLR), two previously 
characterised antimicrobial peptides, were identified in the fermentates of both 
Bacillus cereus and Bacillus thuringiensis isolates. The caseicin peptides were 
subsequently purified by RP-HPLC and antimicrobial assays indicated that the 
peptides maintained the previously identified inhibitory activity against the 
infant formula pathogen Cronobacter sakazakii.  
Conclusions: We report a new method using Bacillus sp. to generate two 
previously characterised antimicrobial peptides from casein. 
Significance and impact of the study: This study highlights the potential to 
exploit Bacillus sp. or the enzymes they produce for the generation of bioactive 
antimicrobial peptides from bovine casein. 
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3.2. Introduction  
Bioactive peptides are generally small (3-50 amino acid residues) 
protein fragments that possess a number of physiological properties and are 
often “encrypted” in a larger protein (Benkerroum, 2010; Clare & Swaisgood, 
2000). These peptides can be released by a number of methods including 
microbial fermentation with live cultures, enzyme hydrolysis using digestive 
enzymes and proteolysis by enzymes from fungal, bacterial or plant sources 
(Korhonen, 2009; Korhonen & Pihlanto, 2006). Milk proteins have been 
recognised as a rich source of bioactives as peptides generated from milk 
protein hydrolysis can exert a broad range of physiological and nutritional 
effects (Benkerroum, 2010; Gill, López-Fandiño, Jorba, & Vulfson, 1996; 
Korhonen & Pihlanto, 2006). From an evolutionary perspective, this may also 
make sense, given that it provides a mechanism to confer health potential 
benefits from mother to baby in the form of  bioactive peptides released in the 
intestine via digestion (Newburg, 2005; Phadke et al., 2005).  
Milk-derived antimicrobial peptides could potentially be used as an 
intrinsic dairy-based protectant against pathogens in powder based food 
products (Hayes et al., 2009). This is particularly true for infant formula which 
can be subject to Cronobacter sakazakii contamination. C. sakazakii is a Gram-
negative opportunistic pathogen, rarely causing illness in adults but has been 
linked to cases of meningitis, bacteraemia and necrotizing enterocolitis in 
infants (Drudy, Mullane, Quinn, Wall, & Fanning, 2006; Gurtler, Kornacki, & 
Beuchat, 2005; NazarowecWhite & Farber, 1997). Powdered infant formula 
(PIF) has been implicated in outbreaks, and in sporadic cases of C. sakazakii 
related illness (Iversen & Forsythe, 2003).  
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The potential use of casein-derived peptides in an industrial setting is 
dependent on the economic feasibility, reproducibility of production, stability 
of the process and its permissive use in a final product.  The generation of  two 
antimicrobial casein-derived peptides, caseicin A and caseicin B  by the 
fermentation of sodium caseinate with Lactobacillus johnsonii DPC 6026 
(formerly Lactobacillus acidophilus) was previously described (Hayes, Ross, 
Fitzgerald, Hill, & Stanton, 2006). The peptides, derived from bovine -s1 
casein, caseicin A (s1-CN f(21-29) IKHQGLPQE) and caseicin B (s1-CN 
f(30-37) VLNENLLR) correspond
 
to the amino acids 6 to 14 and 15 to 22 
respectively, of  the previously characterised antimicrobial peptide isracidin 
(Hill, Lahav, & Givol, 1974).  Caseicin A and B peptides both demonstrated 
antimicrobial activity against the Gram-negative neonatal pathogen 
Cronobacter in lab media (caseicin A minimum inhibitory concentration 
(MIC): 0.05 mmol l
-1
, caseicin B MIC: 0.22 mmol l
-1
)  (Hayes et al., 2006). 
Further investigation confirmed the antimicrobial activity of chemically 
synthesised caseicin A and B albeit at higher concentrations of the peptide 
(McDonnell, Rivas, Burgess, Fanning, & Duffy, 2011; Norberg et al., 2011).  It 
was also demonstrated that caseicin A and B peptides can inhibit the growth of 
other important pathogens such as E. coli, Listeria sp., Staphylococcus aureus, 
Salmonella sp. and Streptococcus mutans (Hayes et al., 2006; McDonnell et 
al., 2011; Norberg et al., 2011). Furthermore, filtered fermentates (≥3-kDa) 
containing the peptides were also successful in controlling Cronobacter levels 
in initial PIF trials (Hayes et al., 2009).   
Subsequent genomic analysis of the L. johnsonii DPC 6026 strain 
revealed however, the absence of a cell-wall proteinase (Guinane et al., 2011) 
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and further experimental analysis indicated inefficient casein degradation by 
this strain itself (unpublished data). Furthermore, members of L. johnsonii and 
closely-related species are producers of D-lactic acid which is not permitted by 
Codex Alimentarius Commision (CAC) standards in infant formula (Connolly, 
Abrahamsson, & Björkstén, 2005) and therefore the use of these organisms 
would not be feasible without the inclusion of extra processing steps. Indeed, 
we have recently tested representatives from seven different Lactobacillus 
species in casein based fermentations but caseicin A and B were not recovered 
in any of the fermentates (unpublished data).  
Bacillus species are the dominant bacteria in industrial fermentations 
for the generation of commercial proteases for food applications (Rao, 
Tanksale, Ghatge, & Deshpande, 1998).  Bacillus cells have a number of 
industrially advantageous traits including short fermentation cycles, high 
growth rates and the ability to secrete a range of hydrolytic enzymes into the 
extracellular media (Gupta, Beg, Khan, & Chauhan, 2002; Schallmey, Singh, 
& Ward, 2004). These enzymes can be active over a wide range of 
temperatures and pH values and so have a broad range of uses in textile, food 
and beverage industries and detergent industries. The proteases of neutral 
Bacillus sp. are optimal near pH 7.0 and have previously been used to modify 
milk proteins (Schallmey et al., 2004). Some species, such as B. subtilis have 
generally regarded as safe (GRAS) status with the Food and Drug 
Administration (FDA) (Zheng & Slavik, 1999) and others have reported 
caseinolytic properties (Mukherjee, Adhikari, & Rai, 2008; Ouoba et al., 
2003). 
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In this study, we investigated the proteolytic ability of various Bacillus 
sp. to degrade casein, including isolates recovered from dairy-based spray-
dried powders. A number of isolates were found to produce a high percentage 
of small peptides (≥5-kDa) and subsequently were investigated for ability to 
produce caseicin A and B during fermentation of sodium caseinate or 
reconstituted skim milk. 
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3.3. Materials and Methods 
3.3.1. Bacterial strains, media and growth conditions 
The Bacillus isolates investigated in this study are outlined in Table 3.1. 
Bacillus sp. were cultured in BHI (Merck, Darmstadt, Germany) broth at 37⁰C 
with agitation or on BHI agar. B. cereus DPC 6559 was isolated in this study as 
a contaminant from skim milk powder on Skim milk agar (Kerry Food 
Ingredients, Tralee, Ireland). The remaining Bacillus isolates investigated were 
obtained from various culture collections (Table 3.1.). Cronobacter 
(Enterobacter) sakazakii NCTC 8155 designated DPC 6440 was selected as a 
target organism for antimicrobial assays as it was originally isolated from a tin 
of milk powder (Farmer III, Asbury, Hickman, & Brenner, 1980) indicating an 
ability to contaminate dried milk products. This strain was propagated in LB 
broth at 37⁰C with agitation or on LB agar.  
 
3.3.2. Fermentation conditions 
The proteolytic capability of bacterial strains was measured by gel 
permeation HPLC (GP-HPLC). Fermentations (5 mL - 8 L) were performed 
using sodium caseinate (2.5% w/v) (Kerry Food Ingredients, Tralee, Ireland) as 
a substrate. Strains were inoculated at 1% (v/v) and incubated at 37°C, with 
mild agitation for 17 h. The pH was measured before and after fermentation. 
Following fermentation, samples were diluted 1/10 and filtered through a 0.45 
nm filter. Samples were analysed on the GP-HPLC using a Waters 626 pump, a 
717 Autosampler, 996 photodiode array detector and 600s controller (Waters 
Corporation, Dublin, Ireland) and applied to a Grace (Grace, Illinois, U.S.A.) 
Nucleosil 100, C18, 5 µm column. Results were read at a wavelength of 280 
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nm. The mobile phase was 30% (v/v) acetonitrile with 0.1% (v/v) trifluroacetic 
acid (TFA). Unhydrolysed casein, subjected to the same processes was used as 
a control.  
 
3.3.3. Detection and production of purified caseicin peptides from Bacillus 
isolates 
Following fermentation with selected Bacillus isolates, fermentates 
were filtered through a size-exclusion 3-kDa centrifugal filter unit (Millipore 
Ltd., Hertfordshire, UK) and subsequent filtrates were analysed for caseicin 
peptide masses using Matrix-assisted Laser Desorption/Ionization-Time of 
Flight (MALDI-TOF) Mass Spectrometry. RP-HPLC was used to further 
purify B. cereus DPC 6559 and B. thuringiensis DPC 6431 3-kDa filtered 
fermentates. Briefly, B. thuringiensis DPC 6431 casein fermentates were 
filtered as described above. Filter permeates were applied to an analytical 
Jupiter Proteo RP-HPLC column (4.6 x 250 mm, 4 μ, 90 Ǻ) running a 10% 
(v/v) to 35% (v/v) acetonitrile 0.1% (v/v) TFA gradient at a flow rate of 1 ml 
per minute over 40 min. Fractions were collected and analysed using MALDI-
TOF mass spectrometry to determine where the caseicin peptides eluted. 
MALDI-TOF Tandem Mass spectrometry (MS/MS) in conjunction with 
Mascot search engine (http://www.matrix-science.com) was used to confirm 
the peptide sequences.  
To generate larger quantities of caseicin A and B peptides 180 ml of B. 
cereus DPC 6559 3 kDa filtrate was lyophilised in a Genevac HT-4X 
evaporator (Genevac Ltd. Ipswich, UK). Dry permeate was resuspended in 
Milli Q water and applied to a Jupiter Proteo (250 x 10mm, 4u, 90 Å) RP-
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HPLC column (Phenomenex, Cheshire, United Kingdom) running a 10-30% 
(v/v)  acetonitrile 0.1% (v/v)  TFA gradient over 40 min. Fractions were 
analysed for the relevant peptide peaks using MALDI-TOF Mass 
Spectrometry. Both caseicin A and caseicin B were further purified by pooling 
the relevant fractions and applying to a RP-HPLC C18 XBridge™ BEH300 
(250 x 10mm, 5u, 300Å) column (Waters Corporation) running a 4-10% (v/v)  
isopropan-2-ol, 0.1% (v/v)  TFA gradient over 40 min for caseicin A and a 10-
18% (v/v)  isopropan-2-ol, 0.1% (v/v)  TFA over 40 min for caseicin B. Both 
peptides were further purified by applying fractions containing the peptide to a 
RP-HPLC Acclaim® (150 x 10 mm, 3µ, 300Å) column (Dionex Ireland Ltd., 
Dublin, Ireland) running a 20-35% (v/v)  methanol 0% (v/v)  TFA gradient 
over 40 min for caseicin A and a 33-46% (v/v)  methanol 0.1% (v/v)  TFA 
gradient over 40 min for caseicin B. Relevant fractions were once again pooled 
and dried. 
 
3.3.4. Determination of antimicrobial activity 
Antimicrobial assays were performed as described previously (Norberg 
et al., 2011) with some modifications. Briefly, caseicin A and caseicin B were 
reconstituted in LB broth at varying concentrations (Fig. 3.2.) and added to a 
96-well plate. C. sakazakii DPC 6440 was added to a final concentration 10
3 
CFU ml
-1
 and incubated with varying dilutions of the relevant peptide at 37°C 
for 24 h in a microtiter plate reader with hourly readings recording the optical 
density (600 nm). Results are given as the mean values of three independent 
determinations ± SEM.   
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3.4. Results 
3.4.1. Casein hydrolysis by Bacillus sp. 
16 Bacillus isolates (Table 3.1.) were investigated for their ability to 
degrade casein and generate caseicin A and B from a casein substrate. Initially, 
the percentage of casein protein hydrolysed to below 5-kDa (Table 3.1.) was 
determined by GP-HPLC analysis. The results demonstrate that a number of 
the Bacillus isolates efficiently cleaved casein with 73-88% of casein 
hydrolysed to peptides <5-kDa compared to the untreated sodium caseinate. In 
contrast, 10 Lactobacillus strains representing seven different species were 
unable to significantly hydrolyse the casein with negligible or limited (~9%) 
hydrolysis to small peptides (data not shown). Strains capable of hydrolysing 
sodium caseinate grew to 10
7
-10
8
 log CFU ml
-1
 (Table 3.1.) and lowered the 
pH of the growth substrate slightly (pH 7.4 to pH 7.0-7.2). Not surprisingly, 
significant growth was not observed in strains unable to hydrolyse sodium 
caseinate.   
 
3.4.2. Bacillus mediated production of caseicin A and caseicin B  
Strains of B. cereus, B. thuringiensis, Bacillus mycoides and Bacillus 
lichenformis  were capable of efficiently hydrolysing casein but only strains of 
the B. cereus and B. thuringiensis species were found to be able to generate the 
caseicin A and B peptides (Table 3.1.) following overnight fermentation of 
sodium caseinate.  The correct peptide masses for caseicin A and B (1049-Da 
and 970-Da, respectively) were detected by MALDI-TOF Mass spectrometry 
on the filtered fermentates of the isolates. Representative strains of both B. 
cereus and B. thuringiensis were taken forward for further investigation. B. 
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thuringiensis DPC 6431 is a previously identified strain isolated from a human 
fecal sample and was found to produce the bacteriocin thuricin CD (Rea et al., 
2010). DPC 6559 was isolated in this study from milk powder and was 
determined by PCR analysis to have certain B. cereus associated toxins (data 
not shown). Following initial detection of correct peptide masses (inset of Fig. 
3.1.), the peptides were purified by RP-HPLC and the amino acid sequence of 
the peptides were confirmed, by MS/MS, to be the caseicin A and B peptides 
identified in the previous study (Hayes et al., 2006). 
 
3.4.3. Antimicrobial assays  
Much of the previous work on the caseicin peptides focused on the 
potential antimicrobial activity against the important PIF pathogen 
Cronobacter sakazakii (Hayes et al., 2009; Hayes et al., 2006; McDonnell et 
al., 2011; Norberg et al., 2011). We investigated in this study if peptides 
produced by Bacillus proteolysis also had similar antimicrobial activity against 
this pathogen. Both peptides produced by Bacillus sodium caseinate 
fermentations were indeed antimicrobial against C. sakazakii (Fig. 3.2.) in 
accordance with Hayes et al., (2006) and Norberg et al., (2011).  Growth of C. 
sakazakii DPC 6440 was inhibited at concentrations of caseicin A of >1.0 
mmol l
-1 
(1.049 mg ml
-1
) compared to the growth of the strain without any 
added peptide (Fig. 3.2A.). Caseicin B also slowed at growth at concentrations 
>1.0 mmol l
-1 
(0.97 mg ml
-1
) but at 3.0 mmol l
-1
 (2.91 mg ml
-1
) complete 
inhibition of pathogen growth over the 24 hours was demonstrated.  
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3.5. Discussion 
In this study, we compared different Bacillus species for their ability to 
degrade casein and release bioactive peptides with antimicrobial activity. To 
achieve this, a total of 16 different isolates were obtained from various 
different sources representing a broad spectrum of Bacillus isolates including 
those found to predominate spray-dried milk powders and other dairy 
environments. Bacillus species are ubiquitous in the dairy drying environment 
and can contaminate dairy products and powders during processing and 
handling. An array of Bacillus species are commonly isolated from such 
powders (Chen, Coolbear, & Daniel, 2004). This study demonstrated   the 
ability of B. cereus and B. thuringiensis strains to degrade casein and produce 
the previously described antimicrobial peptides, caseicin A and B (Hayes et al., 
2006).  
The Bacillus isolates investigated in this study sourced from dairy 
environments all efficiently hydrolysed sodium caseinate with the exception of 
B. coagulans LMG 6326 (Table 3.1.). Only members of B. cereus and B. 
thuringiensis species however generated the caseicin A and B peptides 
following fermentation of sodium caseinate. The processes used to generate 
bioactive peptides must be reproducible and efficient to be considered in an 
industrial context. The Bacillus isolates used in this study reliably produced the 
caseicin peptides during fermentation and did not require media 
supplementation, pH control, agitation or anaerobic conditions. The 
antimicrobial activity of the Bacillus produced caseicin A and B were also 
confirmed in this study (Fig. 3.2). 
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Due to the non-GRAS status of many Bacillus strains, the use of the 
fermentates directly generated in this study is not a feasible option (especially 
for PIF). In contrast, Bacillus species such as B. subtilis and B. lichenformis are 
considered GRAS organisms and possess many traits that make them attractive 
in an industrial setting and are seen as excellent hosts for the production of 
heterologous proteins (Schallmey et al., 2004). Strains of these species 
however, were not successful in producing the particular antimicrobial peptides 
studied in this work. As caseicin A and B generation was found to be a 
common feature of the B. cereus and B. thuringiensis isolates investigated 
(Table 3.1), it is likely that this is as a result of the action of conserved 
proteolytic machinery present in these strains. B. cereus and B. thuringiensis 
are both group I bacilli, indistinguishable by 16S rRNA typing and therefore 
are very genetically closely related (Radnedge et al., 2003). Genomic analysis 
of the B. cereus (Ivanova et al., 2003) and B. thuringiensis (Zhu et al., 2011) 
genomes indicate an almost identical protease complement dominated by 
members of the neutral protease (npr) enzymes and thermolysin-like M4 family 
of peptidases.  These enzymes have a number biotechnological applications 
(Adekoya & Sylte, 2009) and have previously been shown to generate 
bioactive peptides from casein (Mizuno, Nishimura, Matsuura, Gotou, & 
Yamamoto, 2004). Many species of the genus Bacillus generate a range of 
thermostable extracellular enzymes, a number of which have industrial 
applications (Schallmey et al., 2004; Vecerek & Venema, 2000). If possible 
utilizing commercially available industrial enzymes in this manner is more cost 
effective than using an organism naturally producing an enzyme (Mizuno et 
al., 2005).  While the majority of casein-derived bioactive peptides have to 
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date been generated using gastrointestinal enzymes (Korhonen & Pihlanto, 
2006), the use of Bacillus sp. enzymes could lead to the discovery of further 
novel bioactives. The results presented in this study demonstrated the potential 
to produce such bioactive peptides from Bovine casein using Bacillus species.  
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Table 3.1. Bacillus strains screened for caseicin A and B production following 
overnight fermentation 
 
 
    
a
 NCIMB; The National Collection of Industrial, Marine and Food Bacteria 
b 
DPC collection; Dairy Product Collection, Moorepark Food Research Centre, Fermoy, 
Co. Cork 
, Ireland 
c 
LMG; BCCM/LMG Bacteria collection 
d 
BGSC; Bacillus Genetic Stock Centre 
1
 (Rea et al., 2010) 
2
 (Simpson, Fitzgerald, Stanton, & Ross, 2004) 
   
Isolates 
Log CFU 
ML
-1
 
% Casein Hydrolysed < 
5-Kda 
Caseicin A/B 
production Source 
Bacillus thuringiensis NCIMB 701132 2.5x10
7
 82.69±0.80 Yes Unknown 
Bacillus thuringiensis DPC 64311 3.5x10
7
 84.84±0.62 Yes 
Human Fecal 
Sample 
Bacillus thuringiensis NCIMB 701157 4.3x10
7
 74.06±0.84 Yes Unknown 
Bacillus cereus  NCIMB 700577 7.2x10
7
 85.04±0.59 Yes Milk 
Bacillus cereus  NCIMB 700579 4.6x10
7
 88.00±0.78 Yes Milk 
Bacillus cereus DPC 38052 4.3x10
7
 84.91±0.67 No Milk powder 
Bacillus cereus DPC 6559 8.6x10
7
 87.85±1.3 Yes Milk powder 
Bacillus coagulans LMG 6326 6.3x10
4
 No Hydrolysis No Milk powder 
Bacillus firmus LMG 7125 3.2x10
4
 4.37±0.89 No Soil 
Bacillus lichenformis DPC 3803 4.6x10
7
 82.57±0.94 No Milk powder 
Bacillus lichenformis DPC 6337 3.2x10
7
 86.95±0.73 No Processed cheese 
Bacillus mycoides DPC 6335 5.8x10
7
 88.83±0.64 No Processed cheese 
Bacillus stearothermophilus DPC 3802   3.1x10
7
 83.86±1.49 No Milk powder 
Bacillus stearothermophilus DPC 3804  5.9x10
7
 86.35±1.48 No Milk powder 
Bacillus atrophaeus LMG 8198 5.0x10
4
 No Hydrolysis No Unknown 
Bacillus subtilis BGSC 168 2.0x10
4
 22.42±0.53 No Soil 
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Figure 3.1. RP-HPLC chromatogram of sodium caseinate incubated with B. cereus 
DPC6559  
for 17 h (A) and RP-HPLC chromatogram of sodium caseinate incubated with  
B. thuringiensis DPC 6431 for 17 h (B) . Arrows indicate location of the caseicin peptides. 
 The inserts shows the MALDI-TOF spectrum of the peptides.  
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Figure 3.2. (A) Effect of caseicin A at various concentrations on the growth of C. 
sakazakii DPC 6440 in LB broth at 37°C. Symbols: ♦, 2.0 mmol l-1 caseicin A; ■, 1.0 
mmol l
-1
 caseicin A; ▲, 0.75 mmol l-1 caseicin A;○, C. sakazakii DPC 6440 and LB broth 
only; □, LB broth only. (B) Effect of caseicin B at various concentrations on the growth of 
C. sakazakii DPC 6440 in LB broth at 37°C. Symbols: ♦, 3.0 mmol l-1 caseicin B; ■, 1.0 
mmol l
-1
 caseicin B; ◊, C. sakazakii DPC 6440 and LB broth only; □, LB broth only.   
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4.1. Abstract 
The potential of producing the antimicrobial peptide caseicin A 
(IKHQGLPQE) from a casein substrate using a commercial proteolytic enzyme 
was assessed in silico and confirmed in vitro. Thermolysin (EC 3.4.24.27) and 
thermolysin-like enzymes (EC 3.4.24.28) were predicted by bioinformatic-
aided analysis to be the likely candidates to liberate the bioactive peptide from 
-S1-casein. Industrial sources of the thermolysin enzyme were then 
experimentally proven, under various conditions of hydrolysis, to liberate the 
1049 Da caseicin A peptide from milk substrates at both lab and pilot scale. 
The antimicrobial ability of the filtered hydrolysates (<3kDa membrane) to 
reduce pathogen numbers spiked in infant formula was subsequently 
confirmed. During this process a second peptide, generated after hydrolysis 
with a specific enzyme, duplicate in size to caseicin A was identified and 
isolated. A synthetically generated peptide of identical amino acid sequence to 
this novel peptide, caseicin T (VFGKEKVNE), proved to have antimicrobial 
activity against a number of Cronobacter strains.  In conclusion, this study 
presents the potential development of an industrial-grade method to produce 
milk-derived bioactive peptides.  
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4.2. Introduction 
Milk proteins provide a natural source of bioactive peptides with 
potential health benefits and applications in the food industry. The release of 
these peptides from milk components is achieved either by hydrolysis using 
digestive proteases (Clare & Swaisgood, 2000) through food processing or by 
microbial enzymes in fermented products (Agyei & Danquah, 2011; Fitzgerald, 
2006). Peptides derived from milk proteins, in particular, can exert numerous 
physiological benefits and milk proteins are seen as an important reservoir for 
bioactive peptides (Benkerroum, 2010; Ryan, Ross, Bolton, Fitzgerald, & 
Stanton, 2011). These bioactive peptides are known to contribute to the 
efficacy of functional foods in a number of specific cases (Gu, Majumder, & 
Wu, 2011). In order for bioactive peptides to become an industrially feasible 
option, peptides need to be released efficiently, economically and at 
sufficiently high enough quantities for application (Ross, Stanton, Hill, & 
Fitzgerald, 2007). Enzymatic hydrolysis is seen as a favourable method to 
generate milk bioactive peptides due to the lack of residual organic solvents or 
toxic chemicals in the end products. Bacterially-derived enzymes, in particular, 
are seen as advantageous due to the relatively lower costs. The majority of 
proteases generated by microorganisms are produced on the cell membrane 
making their harvesting and purification relatively economic  (Agyei & 
Danquah, 2011; Zambrowicz, Timmer, Polanowski, Lubec, & Trziszka, 2012). 
Previous studies from our group identified two casein-derived 
antimicrobial peptides, caseicin A (IKHQGLPQE) and caseicin B 
(VLNENLLR), with potential applications as dairy-based protectants against 
pathogens in powdered foods (Hayes et al., 2009; Hayes, Ross, Fitzgerald, 
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Hill, & Stanton, 2006).  The caseicin A and B peptides correspond to f(21-29) 
and f(30-37) respectively of bovine S1-casein and together represent amino 
acids 6-23 of the characterised antibacterial peptide isracidin (Hayes et al., 
2006; Hill, Lahav, & Givol, 1974). Both peptides were found to inhibit the 
neonatal Gram-negative pathogen Cronobacter sakazakii in lab media and as 
part of fermentates in powdered infant formula (PIF) trials (Hayes et al., 2009; 
Hayes et al., 2006). Further work demonstrated their ability to inhibit other 
important Gram-negative pathogens including Salmonella and Klebsiella and 
the Gram-positive pathogen Staphylococcus aureus (McDonnell, Rivas, 
Burgess, Fanning, & Duffy, 2011; Norberg, Connor, et al., 2011).  
The enzymatic reactions responsible for the release of caseicin A and B 
from bovine sodium caseinate were predicted to be as a result of the combined 
action of a cell wall proteinase and 3 endopeptidases as a result of fermentation 
with the Lactobacillus johnsonii (previously Lactobacillus acidophilus) DPC 
6026 strain (Hayes et al., 2006).  More recent work however, demonstrated that 
a common feature of Bacillus cereus and Bacillus thuringiensis strains is their 
ability to hydrolyse casein to produce both the caseicin A and B peptides 
following an overnight fermentation (Kent et al., 2012). Members of Bacillus 
sp. are well documented to be efficient in hydrolysing casein and enzymes 
from many sources of Bacillus are exploited at an industrial scale and form key 
components of industrial biotechnology (Rao BM, 1998). The use of Bacillus 
cells or their lysates to directly produce the caseicin A and B antimicrobial 
peptides, however, is not an industrially feasible option (Kent et al., 2012).  A 
potential food-grade and cost effective solution is to employ already available 
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commercial Bacillus-derived enzymes that can liberate the antimicrobial 
peptides.  
Computer aided design can theoretically predict the proteolytic 
cleavage sites among target proteins and therefore determine the possible 
bioactive peptides that can be released from complex systems (Minikiewicz, 
2008). Previously Gu et al. demonstrated the potential of computer aided 
design by using an in silico approach to evaluate the suitability of various 
protein substrates as precursors of ACE inhibitory peptides (Gu et al., 2011). 
The aim of this study was to use genomic and enzyme analysis to select 
commercial enzymes that could be used to release the caseicin peptides from 
casein as a basis to generate powders sufficient to contribute to the biosafety of 
infant milk formula. The antimicrobial activity of the powders to inhibit 
pathogen numbers was also demonstrated.  
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4.3. Materials and Methods 
4.3.1. Bacterial strains and culture conditions. 
C. sakazakii DPC6440 (NCTC 8155), Salmonella typhimurium LT2 
and S. aureus SA113 were used as indicator organisms in powdered food trials. 
Other Cronobacter isolates used in synthetic caseicin T minimum inhibitory 
concentration (MIC) assays are listed in Table 4.1. Cultures were maintained at 
37C in Luria-Bertani (LB) media (Oxoid; Basingstoke, UK) under aerobic 
conditions. 
   
4.3.2. Bioinformatic analysis.   
The genome sequences of Bacillus cereus Q1 (CP0000227), B. 
thuringiensis str. Al Hakam (CP0000485) and B. thuringiensis BMB171 
(CP0001903) were used for analysis of their protease complement.  Protease 
enzymes were analysed using http://www.uniprot.org/, BRENDA (Chang, 
Scheer, Grote, Schomburg, & Schomburg, 2009) at http://www.brenda-
enzymes.org/ and using the MEROPS database (Rawlings & Barrett, 1999; 
Rawlings, Morton, Kok, Kong, & Barrett, 2008) at http://merops.sanger.ac.uk/. 
The cleavage specificity of the thermolysin enzyme was analysed using peptide 
cutter http://expasy.org/tools/peptidecutter and the BIOPEP database 
(Minkiewicz, Dziuba, Iwaniak, Dziuba, & Darewicz, 2008) 
http://www.uwm.edu.pl/biochemia. 
  
4.3.3. Substrates and enzymes. 
The proteases used were Thermolysin, Neutrase 0.8L, Protamex, 
Flavourzyme 500L (Sigma-Aldrich, St. Louis, MO), Thermoase PC10F, 
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Protease N, Newlase F, Protin NY100, Protease A, Protease M, Protease P, 
Acid Protease A (Amano Enzyme, Nagoya, Japan), and Protex 14L (Genencor, 
Rochester, NY, USA).  Casein substrates included sodium caseinate and 
reconstituted skim milk (RSM) (Dairygold, Cork, Ireland) to 5 % and 10 % 
w/v respectively.   
 
4.3.4. Enzymatic hydrolysis.  
Enzymes were added to the casein substrates at varying concentrations 
(0.1 -2% w/v) and incubated at 37-65°C for 6-20 h to optimise hydrolysis. The 
pH was determined following hydrolysis. The hydrolysates were heated to 
95⁰C for 20 mins to inactivate the enzyme and then filtered through a size-
exclusion 3kDa spiral cartridge filter (Millipore Ltd., Hertfordshire, UK). The 
filtrates were then taken forward for Matrix-assisted laser 
desorption/ionization-time of flight (MALDI-TOF) Mass spectrometry (MS) 
and Reverse phase-high-performance liquid chromatography (RP-HPLC) 
analysis. Pilot-scale trials were determined at 10 L as above and subsequently 
spray-dried (Fox, 2003) to produce a bioactive powder. 
Gel permeation-HPLC (GP-HPLC) as described previously (Kent et al., 
2012) was used to determine  the optimum conditions for casein hydrolysis 
using the PC10F thermoase enzyme. Briefly, samples were diluted 1/10 
following enzymatic treatment under relevant conditions and filtered through a 
0.45 nm filter. Analysis on the GP-HPLC were performed using a Waters 626 
pump, 600s controller and a 996 photodiode array detector (Waters 
Corporation, Dublin, Ireland) and were applied to a Grace Nucleosil 100, C18, 
5-µm column (Grace, Il., USA). The mobile phase was 30% (v/v) acetonitrile 
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with 0.1% (v/v) trifluroacetic acid (TFA). Results were read at a wavelength of 
280 nm. Sodium caseinate substrate was assayed at a concentration of 2.5%, 
5% and 10%. Each percentage was treated with the enzyme at 2.5 mg/ml, 
5mg/ml or 10 mg/ml. Each of these was in turn incubated at either 37°C, 50°C 
or 60°C. The degree of hydrolysis was measured at T0, T1, T2, T4, and T6h.   
 
4.3.5. Mass Spectrometry (MS) and Reverse Phase (RP)-HPLC analysis of 
hydrolysates. 
The permeates containing peptides of <3kDa were applied to a Jupiter 
Proteo (250 x 10mm, 4u, 90 Å) column (Phenomenex, Cheshire, United 
Kingdom) running a 10-30% acetonitrile 0.1% TFA gradient over 40 minutes. 
Fractions were analysed for the relevant peptide peaks using MALDI-TOF MS.  
Caseicin A was further purified by pooling the relevant fractions and running 
on a HPLC fitted with a RP C18 XBridge™ BEH300 ( 250 x 10mm, 5u, 300Å 
) column (Waters Corporation) running a 4-10% isopropan-2-ol, 0.1% TFA 
gradient over 40 minutes.  Further purification if necessary was completed by 
applying fractions containing the peptide to a RP_HPLC Acclaim® ( 150 x 10 
mm, 3µ, 300Å ) column (Dionex Ireland Ltd., Dublin, Ireland ) running a 20-
35 % methanol 0.1% TFA gradient over 40 minutes.  The caseicin A peptide 
was then lyophilised in a Genevac HT-4X evaporator (Genevac Ltd. Ipswich, 
UK). The amino acid sequence of a second peptide, caseicin T was verified by 
MS/MS. The MS/MS positive ion, averaged data +/- 0.8 Da was searched 
using the Mascot engine (http://www.matrix-science.com) with the following 
parameters: Database: NCBInr database or Swiss Prot, taxonomy: mammalian, 
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Enzyme thermolysin, one missed cleavage and variable modifications 
including methionine modified by oxygen. 
 
4.3.6. Peptide Synthesis 
The caseicin peptides were chemically synthesized using microwave-
assisted solid-phase peptide synthesis (MW-SPPS) with a Liberty CEM 
microwave peptide synthesizer as previously described (Norberg, Connor, et 
al., 2011). Caseicin A was made on H-Glu(OtBu)-HMPB-Chematrix resin and 
purified using RP-HPLC. Caseicin T was made on H-Glu(OtBu)-Wang-Matrix 
Innovation resin. Fractions containing the relevant peptide were identified 
using MALDI-TOF MS. Peptides were pooled and lyophilized as described 
earlier (Norberg, O'Connor, et al., 2011).  
 
4.3.7. MIC determination. 
The Minimum inhibitory concentration (MIC) was determined for C. 
sakazakii DPC6440 using purified thermolytic caseicin A as previously 
described (Norberg, Connor, et al., 2011; Wiedemann, 2006). Synthesized 
caseicin A was also assayed to compare to the enzyme-liberated caseicin A. 
Briefly, serial two-fold dilutions of caseicin A were made in LB broth and 
added to a 96 well plate. C. Sakazakii DPC6440 were cultured in LB broth to a 
final OD600 of 0.5. and then added to plates at a final concentration 10
5 
CFU/mL. After incubation for 16 h at 37°C the MIC was read as the lowest 
peptide concentration that prevented visible growth. Results are given as the 
mean values of three independent determinations. Antimicrobial assays were 
performed as described previously (Kent et al., 2012; Norberg, Connor, et al., 
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2011) with some modifications. Briefly, caseicin T was reconstituted in LB 
broth at varying concentrations and added to a 96-well plate. Pathogenic strains 
(Table 4.1.) were added to a final concentration 10
3
 CFU ml-1 and incubated 
with varying dilutions of the relevant peptide at 37°C for 24 h in a microtiter 
plate reader with hourly readings recording the optical density (600 nm). 
Results are given as the mean values of three independent determinations ± 
SEM.   
 
4.3.8. Infant formula trials.  
Infant formula trials were performed as previously described (Hayes et 
al., 2009) with some minor modifications. Briefly, freeze-dried filtrates were 
reconstituted in water at 50 % w/v. A commercially available brand of infant 
milk was purchased. 25.5 g of infant formula was reconstituted in 180 ml of 
sterile, distilled water and pasteurized at 63ºC for 30 min in a water bath and 
subsequently cooled to room temperature. Pasteurised infant formula was 
dispensed in to 6-ml volumes and the sodium caseinate-thermoase hydrolysate 
was added to the formula at a final concentration of 10 % (wt/v). Controls 
employed included infant milk formula to which no caseicin powder was 
added, formula containing an unhydrolysed casein powder (heat-treated and 
not heat-treated) and or formula containing casein hydrolysed with a randomly 
selected proteases (data not shown). Pathogenic microbes were added to the 
infant formula to a final concentration of 10
1
 – 102 CFU/ml.  Samples were 
incubated at 37ºC and aliquots were taken and plated at T0, T1 and T6. All 
infant formula trials were carried out in triplicate. 
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4.4. Results 
4.4.1. Identification of an enzyme that liberates caseicin A from -S1-
casein. 
Previous work indicated that a conserved feature of the B. thuringiensis 
and B. cereus group is the ability to cleave casein to liberate the caseicin A 
IKHQGLPQE and B VLNENLLR peptides (Kent et al., 2012). Other Bacillus 
species including Bacillus subtilis, Bacillus firmus, Bacillus licheniformis, 
Bacillus stearothermophilus, Bacillus coagulans and Bacillus mycoides were 
tested but were not found to produce the peptides from milk (Kent et al., 2012).  
 In this study, in silico analysis of the available genome sequences from 
B. cereus (Xiong et al., 2009) and B. thuringiensis (Challacombe et al., 2007) 
were used to determine the potential protease gene candidates that may be 
responsible for the proteolytic nature of these species. The M4 family of 
peptidases which most resemble bacillolysin (EC 3.4.24.28) and thermolysin-
like enzymes (EC 3.4.24.27) were predicted to be the most likely group of 
enzymes to have a role in casein degradation (Fig. 4.1a). These enzymes are 
neutral metalloproteases that show specificity for cleavage at hydrophobic 
amino acids but generally have broad substrate specificity. The Neutral 
protease (Npr) enzymes from Bacillus sp. have been well studied for industrial 
production and for elucidation of enzymatic mechanisms (Helmann, 1995; 
Imanaka, Shibazaki, & Takagi, 1986; Vecerek & Venema, 2000). The cleavage 
specificities for Bacillus-derived enzymes on bovine -S1 casein were 
analysed using the ExPASy peptide cutter software (Gasteiger E., 2005) and 
the BIOPEP (Minkiewicz et al., 2008) database.  Although a perfect match to a 
full intact caseicin A peptide was not identified, based on this analysis, 
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thermolysin was the most likely candidate chosen as to liberate caseicin A from 
casein (Fig. 4.1b). 
 
4.4.2. Hydrolysis of casein with commercial enzymes. 
Commercial sources of EC 3.4.24.27 and EC 3.4.24.28 including 
thermolysin and bacillolysin enzymes were obtained in addition to other related 
proteases (EC 3.4.24.4) and selected unrelated commercial proteases from both 
bacterial and fungal sources (Table 4.2). All enzymes were tested for 
proteolytic activity and for the production of caseicin A and B from casein 
substrates.  Although all enzymes could degrade casein, only sources of the 
thermolysin enzyme could produce caseicin A of 1049Da (IKHQGLPQE) 
following hydrolysis (Table 4.2.; Fig. 4.2a.).  Commercial sources of the 
closely related bacillolysin enzymes (Neutrase 0.5L and Protease N) were 
unsuccessful in cleaving casein to produce caseicin A under the conditions 
tested despite the genetic loci identified in the B. cereus and B. thuringiensis 
genomes most resembling the bacillolysin group. Other proteases including 
enzymes both related (EC 3.4.24.4) and unrelated to thermolysin were also 
tested but none were found to release either of the caseicin peptides under the 
conditions of hydrolysis tested (Table 4.2.).  Interestingly, a fungal source of an 
enzyme of the thermolysin family (EC 3.4.24.27; Protease A) also did not 
produce caseicin A following casein hydrolysis indicating the specificity of the 
Bacillus-derived form of the enzyme to produce the peptide (Table 4.2.). The 
caseicin B peptide of 970 Da (VLNENLLR) was not detected in any of 
filtrates. As the BIOPEP database analysis indicates that caseicin B is 
hydrolysed by the thermolysin enzyme (Fig. 4.1b.), it is therefore likely that 
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within the Bacillus cells a separate enzyme or mechanism is responsible for 
caseicin B production.  Further analysis would be required to determine this.  
GP-HPLC indicated that thermoase PC10F efficiently hydrolysed 
caseinate at all temperatures and concentrations investigated (data not shown).  
However, peptides of 1049 Da were only visible by MALDI-TOF MS after an 
incubation >4 h.    
 
4.4.3. Caseicin peptide A production with industrial sources of 
thermolysin. 
Additional investigation by MS and RP-HPLC with two industrial 
sources of thermolysin; Thermoase PC10F (Amano Enzymes) and Protex 14L 
(Genencor) revealed that caseicin A could be liberated from casein under 
varying conditions of hydrolysis including temperature (37-65⁰C), time of 
hydrolysis (6-24h) and using different casein substrates (5% w/v Sodium 
caseinate and 10% RSM). An enzyme to substrate ratio of 0.5% w/v was 
optimal for caseicin A production. RP-HPLC (Fig. 4.2a. and 4.2b.) analysis 
revealed a yield significantly higher (~9-11 times greater) than achieved by 
bacterial fermentation (R. Kent et al., 2012) 
Ten litre pilot-scale trials were then performed to investigate if caseicin 
A was produced in sufficient quantities on scale up and if the bioactivity was 
stable.  Hydrolysates were heat treated at 95⁰C to inactivate the enzyme and 
subsequently spray dried to create a bioactive powder. MS and RP-HPLC 
analysis on resuspended powders demonstrated the presence of caseicin A in 
the spray dried powders (not shown).  
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Caseicin T generation was only apparent with Hydrolysis by 
Thermoase PC10F.   
 
 
4.4.4. Antimicrobial activity of thermolytic-released caseicin A 
The 1049Da caseicin A peptide IKHQGLPQE was purified by RP-
HPLC and MICs were performed as previously described (Norberg, Connor, et 
al., 2011) against a known sensitive strain, Cronobacter sakazakii DPC 6440 
(Hayes et al., 2006; Norberg, Connor, et al., 2011).  Purified sources of the 
peptide were obtained from 3 kDa hydrolysates that had been subjected to heat 
treatment to inactivate the thermolysin enzyme and a control which had not 
been heat treated.  As the thermolysin enzyme is ~36 kDa it would also be 
removed by filtration.  MIC data indicate that the both heat-treated and non-
heat treated thermolytic-liberated caseicin A resulted in an MIC of 0.625mM 
which is identical to the MIC achieved with the synthesised peptides in this 
study and in previous work (Norberg, Connor, et al., 2011).   
 
4.4.5. Infant formula trials 
Freeze-dried <3kDa Thermoase PC10F hydrolysates were generated 
using a Virtis Advantage freeze-dryer (SP Industries, 935 Mearns Road, 
Warminster, PA, USA) and were added to infant formula preparations at 0-
12.5% w/v and preparations were spiked with the pathogens C. sakazakii, S. 
aureus and S. typhimurium and trials were performed as previously described 
(Hayes et al., 2009). A total of four thermoase powders were produced to 
determine if a 3 kDa filtration and/or heat treatment would influence 
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antimicrobial activity. The function of the heat treatment step is to inactivate 
the thermolysin enzyme as it cannot be present in a final product. The size of 
the thermolysin enzyme is 36 kDa so if a filtering step is included (~3 kDa); it 
removes the thermolysin from the hydrosylate powders however. If the 3 kDa 
filtration step is omitted, then it would have to be heat treated to ensure that the 
enzyme was not active. Heat treatment at 95ºC for 20 min is documented to 
inactivate the thermolysin enzyme (Matthews BW, Weaver LH & Kester WR, 
1974). A 3 kDa filtration step was used to purify and concentrate the active 
peptide. The milk was spiked with S. aureus SA113, 8325-4, Newman, S. 
typhimuirum LT2 and C. sakazakii DPC6440 each at a level of 10
1
-10
2
 
CFU/ml and incubated for 6 h at 37˚C. 
The thermoase powder exhibited similar activity levels to those 
observed for the reconstituted skim milk trials. While results varied slightly 
between strains, a 10
2
-10
3 
CFU/ml reduction in growth was observed with the 
thermoase hydrosylate powders. Interestingly, C. sakazakii DP6440 was 
completely inhibited following 6 hr incubation with the thermoase treated 
hydrosylate powder which had not been filtered or heat treated. The growth of 
the other organisms were all affected in a similar manner, with a 10
2 
CFU/ml -
10
3 
CFU/ml reductions in growth being observed (Fig 4.3.). 
 
4.4.6. Antimicrobial activity of synthetic caseicin T 
The antimicrobial activity of synthetically generated caseicin T was 
assayed against a number of pathogens including four Cronobacter strains. The 
peptide completely restricted growth in the Cronobacter strains assayed at a 
concentration of 2.5 mM (2.625 mg ml
-1
). Caseicin T also prevented the 
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growth of a Salmonella strain at the same concentration. The peptide did not 
have an inhibitory effect on a Staphylococcus aureus strain (Fig. 4.4.).  
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4.5. Discussion  
 Milk-derived peptides with antimicrobial activity have much industrial 
potential as they have the advantage of being derived from a safe and 
economical source.  Their large-scale manufacture and commercial 
exploitation however is still limited as industrial scale production is often not 
possible due to lack of suitable economical technologies. In general they also 
suffer from the disadvantage of having relatively high MIC values which are in 
the mM range compared to classical antimicrobial peptides such as defensins 
and bacteriocins with MIC value in the µM – nM range. Bioactive peptides 
may be produced either by in vitro enzymatic hydrolysis or by in situ microbial 
fermentation of food proteins. The use of enzymatic hydrolysis to produce 
natural bioactives is preferential to microbial fermentation for ease of 
scalability and as it not influenced by microbial growth parameters. 
 In this study, enzyme hydrolysis was used to liberate the caseicin A 
peptide (IKHQGLPQE) from casein previously described to be released as a 
result of microbial fermentation (Hayes et al., 2006; R. Kent et al., 2012) 
Thermolysin and thermolysin-like enzymes were predicted by bioinformatic 
analysis to be the likely candidates to release the peptide from -S1 casein 
(Fig.4.1.). The in silico generation of a peptide of interest before wet-lab 
production allows the streamlining of the process (Agyei & Danquah, 2011; 
Wang, Zhang, Wang, Feng, & Shan, 2011).  Improved protein and peptide 
databases increase the feasibility of predicting new and more potent bioactives 
prior to the beginning of time consuming laboratory synthesis. Experimental 
analysis using a number of commercial enzymes indicated that the peptide 
release was specific to the Bacillus-derived thermolysin enzyme (EC 3.4.24.27) 
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as the closely related bacillolysin enzymes (EC 3.4.24.28) or the Aspergillus-
derived thermolysin were not successful in producing caseicin A under the 
conditions tested (Table 4.1.).   
 The generation of a previously unidentified antimicrobial peptide, 
caseicin T illustrates the fact that targeted production of a peptide can lead to 
unexpected bi-products. Although high concentrations of the peptide were 
required inclusion with another antimicrobial might allow for the creation of an 
effective hurdle system to prevent growth of contaminating bacteria. It should 
be noted that extensive hydrolysis of milk proteins, which was performed in 
this study leads to the generation of a large number of milk peptides. In this 
study a full screen of every resultant peptide was not undertaken and there is a 
possibility that numerous other peptides possess bioactivity. Indeed some 
unidentified peptides may also contribute to the antimicrobial activity observed 
in the infant formula trials described in this chapter. Caseicin T was further 
investigated due the peptides molecular size similarity with caseicin A.  
 Thermolysin is the best studied member of the zinc endopeptidase 
family and is currently used in the food industry as a peptide and ester 
synthetase in the production of the artificial sweetener aspartame (Ager et al., 
1998; Erbeldinger et al., 2000; Ulijn et al., 2001).  Food-grade forms of 
thermolysin are available as partially purified sources as Thermoase PC10F 
(Amano enzyme) and Protex 14L (Genencor, Danisco) which were verified in 
this study or as an immobilised form (Chirax) which would allow enzymatic 
hydrolysis under milder and more controlled conditions. Sources of these 
enzymes are readily available in pilot and industrial scale which allows for 
easy scale up and are derived from Bacillus thermoproteolyticus which is a 
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food-grade organism.  As the principal problem in bioactive peptide generation 
is the prohibitive cost of their manufacture (manufacturing costs can range 
from $50-400 per gram) (Marr, Gooderham, & Hancock, 2006) a streamlined 
enzymatic method shows increased feasibility at an industrial level.    
The antimicrobial activity of the thermolytic-liberated caseicin A in a 
purified form and as part of powdered filtrates was also confirmed in this 
study.  A major difficulty in development for industrial production however, is 
the need for a filtration step at present within the process. It is estimated that 
separation and purification stages account for up to 70 % of the capital and 
operating costs (Brady, Woonton, Gee, & O'Connor, 2008). Investigations into 
novel methods to isolate and purify bioactive peptides in a timely and 
economical manner are on-going (Agyei & Danquah, 2011). 
 Further trials with a range of powdered food products and pathogens 
are necessary to determine the full potential of the thermolysin generated 
powders described in this study. Although the powdered hydrolysates did not 
have a significant reduction in bacterial cells, growth was slowed indicating its 
ability to prevent the outgrowth of bacterial cells in food.  
In conclusion, computer aided analysis identified in this study 
industrially available enzyme that can be potentially applied at pilot scale.  
This indicates the opportunity to tailor the release of specific peptides from 
complex sources by use of different known proteases singly or in combination 
for a greater diversity of potential functional food products.   
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Table 4.1. Bacterial strains challenged with synthetic caseicin T 
Strain Culture Collection No. Source 
C. sakazakii DPC6440 Dried Milk powder 
C. sakazakii DPC6522 Blood 
C. sakazakii DPC6523 Cerebrospinal Fluid 
C. sakazakii DPC6528 Cerebrospinal Fluid 
C. sakazakii DPC6531 Brain Tissue 
S. typhimurium    DT 104 Unknown 
Staph. aureus 4330 Unknown 
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Table 4.2. Commercial and Food grade enzymes used in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
Lab-grade form of enzyme used
 
nd; No peptide detected 
 
 
 
 
 
 
 
 
 
 
 
 
 nd EC 3.4.21.14 Bacillus sp. Protamex
a 
 nd EC 3.4.23.18   Aspergillus niger Acid protease 
A 
 nd EC 3.4.21.63   Aspergillus melleus Protease P 
nd EC 3.4.23.18  Aspergillus oryzae  Protease M 
 nd EC 3.4.24.27   Aspergillus oryzae Protease A 
 nd EC 3.4.23.21 Rhizopus riveus Newlase F 
 nd EC 3.4.24.4 Bacillus subtilis Protin NY100 
 nd EC 3.4.24.28 Bacillus subtilis Neutrase 0.5L
a
 
 nd EC 3.4.24.28 Bacillus subtilis Protease N 
1049 Da 
IKHQGLPQE EC 3.4.24.27 
Bacillus 
thermoproteolyticus  Protex 14L 
1049 Da 
IKHQGLPQE EC 3.4.24.27 
Bacillus 
thermoproteolyticus  
Thermoase 
PC10F 
1049 Da 
IKHQGLPQE EC 3.4.24.27 
Bacillus 
thermoproteolyticus  Thermolysin
a 
Caseicin A 
Peptide 
Enzyme 
group Source/Organism  Protease 
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Figure 4.1. Protein representation of the thermolysin and bacillolysin enzymes 
with related functional domains (a) and predicted thermolysin cleavage sites on 
alpha-S1-casein (b). 
  
Thermolysin 
EC 3.4.24.27 
Bacillolysin 
EC 3.4.24.28 
 1  25                           228                                            546   
1   28                          221                                             521 
Signal                 Propeptide                                Mature Chain 
Peptide               % identity                                  % identity 
M4 
M4 M4-C 
M4-C 
RPKHPIKHQGLPQEVLNENLLR
F 
IKHQGLPQE 
1049Da 
-alpha-S1-casein 
T            T           T T         T T   T  
a. 
b. 
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Figure 4.2. RP-HPLC of thermolysin produced caseicin A (b) and confirmed 
MS of the purified fraction (b). 
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(d)  
 
 
 
(e) 
 
 
Figure 4.3. Effect of <3kDa thermolysin-hydrolysate in reconstituted infant 
formula at 37⁰C with unhydrolysed fermentate as a control against C. sakazakii 
DPC6440 (a), Salmonella LT2 (b) and Staphylococcus aureus 8325-4 (c), S. 
aureus Newman (d) and S. aureus SA113 (e). The indicator strains were 
incubated at 37°C for 6 h in the presence of  10%  caseicin hydrosylate in 
reconstituted powdered infant formula. The mean of triplicate values were 
graphed and the standard deviations were also included.   ; represents the 
indicator incubated with unhydrolysed casein,   ; represents the indicator 
incubated with 3Kda filtered casein powders hydrolysed with thermoase 
PC10F.  ; represents the indicator incubated with casein powder hydrolysed 
with thermoase PC10F (unfiltered).      
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Figure 4.4. Effect of synthetic caseicin T on the growth of various strains in 
LB broth at 37°C. (A) C. sakazakii DPC6522, (B) C. sakazakii DPC6523 (C) 
C. sakazakii DPC628 (D) C. sakazakii DPC6531 (E) Salmonella DT109 (F) 
MR Staph. aureus × represents the positive control; X represents caseicin T at 
a concentration of 1.25 mM        represents caseicin T at 2.5 mM concentration. 
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Chapter 5 
 
Recombinant Lactobacillus paracasei strain producing active gut hormone 
Glucagon-Like peptide-1 analogue 
 
Robert M. Kent, Helena M. Stack, Paula M. O’Connor, Colin Hill, Gerald F. 
Fitzgerald, Seeley, R.J., Catherine Stanton and R. Paul Ross 
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5.1. Abstract: 
Glucagon-like peptide-1 (GLP-1) is an important incretin hormone 
secreted by intestinal L-cells in response to nutrient ingestion. Administration of 
the peptide leads to improvement of glycaemic control in type 2 diabetes patients 
but therapeutic use of the peptide is limited as it has a short biological half-life 
due to the action of the aminopeptidase dipeptidyl peptidase IV (DPP IV) which 
is ubiquitously expressed throughout mammalian tissues. In this study, we 
investigated whether GLP-1 could be overexpressed by an intestinal 
Lactobacillus strain using the machinery for production and secretion of the 
bacteriocin pediocin. To achieve this, the operon required for pediocin 
production was first cloned into the expression vector pNZ44. The nucleotide 
sequence for KGLP-1, a DPP-IV resistance native GLP-1 analogue was then 
substituted for the pediocin structural gene using splicing overlap excision PCR. 
Both plasmid constructs were then electro-transformed into the Lactobacillus 
paracasei NCC 338 to generate two transformants, Lactobacillus paracasei DPC 
PED (pediocin producer) and Lactobacillus paracasei DPC 6770 (KGLP-1 
producer). Transformants were screened for relevant heterologous peptide 
production using MALDI-TOF mass spectrometry. Lactobacillus paracasei DPC 
PED was screened for pediocin production using well diffusion assays. 
Lactobacillus paracasei DPC 6770 was screened for KGLP-1 production and in-
vitro insulinotropic activity. Our results illustrate a method to generate 
recombinant strains capable of producing bioactive peptides with the potential to 
improve human health.  
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5.2. Introduction 
The incretin effect is the term used to describe the greater insulin 
response induced by oral glucose load compared to the response induced by 
isoglycemic intravenous glucose infusion (Doyle & Egan, 2007; Elrick, 
Stimmler, Hlad, & Arai, 1964; Kazakos, 2011). This effect is  principally 
attributed to two incretin hormones, namely glucose-dependent insulinotropic 
peptide (GIP) and Glucagon-like peptide-1 (GLP-1) (Doyle & Egan, 2007; Holst, 
2007; Kazakos, 2011). Both hormones are post-prandially released and potentiate 
glucose-dependent insulin secretion by the pancreas (Drucker, 2006). The 
intensification of these hormones, especially GLP-1 has recently been the subject 
of extensive research in order to provide novel treatments for type 2 diabetes 
(Pontarolo et al., 2013). The majority of GLP-1 is generated in enteroendocrine 
L-cells located in the distal gut after food intake and is found in two equipotent 
active forms, namely GLP-1 (7-37) and GLP-1 (7-36) amide (Drucker & Nauck, 
2006). Although exogenous GLP-1 lowers post-prandial glucose levels in type 2 
diabetes patients (Siegel et al., 1999), the peptide is rapidly inactivated (2-3 min) 
by dipeptidyl peptidase IV (DPP-IV) (Baggio & Drucker, 2007; Mentlein, 
Gallwitz, & Schmidt, 1993). DPP-IV is a ubiquitous enzyme expressed 
throughout mammalian tissues and organs (Augustyns et al., 1999) which 
selectively removes the N-terminal dipeptide from peptide sequences with 
alanine or proline in the second position (Lambeir, Durinx, Scharpé, & De 
Meester, 2003). In the case of GLP-1 DPP-IV cleaves the His
7
-Ala
8
 dipeptide 
from the N-terminus of GLP-1 generating GLP-1 (9-36) amide. This truncated 
form of GLP-1 has no known biological activity and may act as a GLP-1 
receptor agonist further inhibiting the action of intact GLP-1 (Knudsen & Pridal, 
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1996). Accordingly, the development of longer acting GLP-1 analogues, resistant 
to enzymatic cleavage would greatly improve the therapeutic potential of the 
peptide as a type 2 diabetes treatment (Chen et al., 2007; Siegel et al., 1999).   
  A number of strategies have been studied to overcome the therapeutic 
limitations caused by the short half-life of GLP-1 including the use of DPP-IV 
inhibitors, the generation of recombinant GLP-1-human serum albumin fusion 
proteins capable of prolonging biological half-life and designing structural 
analogues resistant to DPP-IV (Dou et al., 2008). Previous research 
demonstrated that the addition of the amino acid lysine to native GLP-1 before 
the N-terminal histidine of the sequence conferred resistance to DPP-IV 
mediated cleavage. This analogue of GLP-1, designated KGLP-1 also maintained 
insulinotropic activity (Gao et al., 2009). Previously, overlapping PCR 
technology was used to generate plasmid constructs that were subsequently 
transformed into Pichia pastoris strains capable of expressing a GLP-1 human 
albumin ((GLP-1A2G)2-HSA) fusion protein resistant to DPP-IV (Dou et al., 
2008).  
In this study, two recombinant L. paracasei strains were generated, one 
containing the operon responsible for pediocin production and export, and one 
containing the same operon with the mature pediocin sequence replaced by the 
nucleotide sequence responsible for KGLP-1. Both strains were analysed for 
relevant peptide production via Matrix-assisted laser desorption ionization time 
of flight (MALDI-TOF) mass spectrometry and High performance liquid 
chromatography (HPLC). Bioactivity of the pediocin producing strain and the 
KGLP-1 producing strain was analysed by well diffusion assay and tissue culture 
using insulin producing RINm5F Beta cells, respectively.    
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5.3. Materials and Methods 
5.3.1. Reagents 
Standard GLP-1 (Product no.G9416) was  from Sigma (St. Louis, MO, 
USA) and synthetic KGLP-1 
(KHVEGTFTSDVSSYLEGQAAKEFIAWLVKGRG) was chemically 
synthesized in Teagasc Food Research Centre, Moorepark (Fermoy, Co. Cork, 
Ireland) using a Liberty CEM microwave peptide synthesizer as previously 
described (Norberg et al., 2011) with minor alterations. Briefly KGLP-1 was 
generated on H-Gly-HMPB-Chematrix resin (PCAS Biomatrix Inc., Quebec, 
Canada) and purified using RP-HPLC. Cell culture media was obtained from 
LGC (LGC Standards, Queens Road, Teddington, Middlesex, TW11 0LY, 
England). Meso Scale Diagnostic (MSD) plates were supplied with reagents and 
were obtained from Meso Scale Discovery (Meso Scale Diagnostics, LLC, 9238 
Gaither Road, Gaithersburg, MD 20877, USA). Remaining reagents used in this 
study were of analytical grade and are commercially available.   
  
5.3.2. Bacterial strains and culture conditions 
The strain L. paracasei ssp. paracasei NFBC 338 (L. paracasei NFBC 
338) is a human gastrointestinal tract isolate obtained from University College 
Cork (UCC) under a restricted materials transfer agreement and was cultured at 
1% (v/v) in de Man, Rogosa and Sharpe (MRS) broth (Difco) for ~ 17 h at 37°C 
under anaerobic conditions (anaerobic jars with Anaerocult A Gas Packs [Merck, 
Darmstadt, Germany]). Pediococcus acidilactici DPC 5492 (NCIMB 700993) 
was grown under similar anaerobic conditions at 30°C. L. paracasei DPC 6770 
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and L. paracasei DPC PED strains were grown using the conditions outlined for 
the wild-type strain. Listeria innocua DPC 3572 (Teagasc Food Research Centre, 
Moorepark, Fermoy, Co. Cork, Ireland) was cultivated with brain-heart infusion 
(BHI) medium aerobically at 37°C. 
 
5.3.3. Cell culture 
RINm5F Insulinoma β-cells (Rattus norvegicus) (ATCC-CRL-11605) 
(LGC Standards, Queens Road, Teddington, Middlesex, TW11 0LY, England) 
were cultured in RPMI-1640 (LGC Standards) medium containing 10% (v/v) 
foetal bovine serum, and 1% (v/v) Penicillin-Streptomycin solution (Sigma: Cat. 
No. P0781). All cells were maintained in 75 cm
2
 sterile tissue culture flasks 
(Corning Inc, NY, USA) at 37°C in an atmosphere in 5% CO2. Cells were 
passaged when the confluency of the flasks was approximately 90%. For 
insulinotropic studies, cells were treated with trypsin and seeded into 6 well 
tissue culture plates (Sarstedt, Sinnottstown Lane, Drinagh, Co. Wexford, 
Ireland) at a density of 1 x 10
5 
cells/well. 
 
5.3.4. Molecular cloning procedures 
The nucleotide sequence for KGLP-1 was synthesised using overlap 
extension PCR (OE-PCR) using primers 1, 2, 3 and 4 (Table 5.1.). DNA was 
extracted from P. acidilacti DPC 5492 and the pediocin leader (ped lead) 
sequence was amplified using primers 5 and 6 (Table 5.1.). A splicing overlap 
extension (SOE) PCR reaction using primers 2 and 5 (Table 5.1.) was used to 
combine the KGLP-1 sequence and pediocin leader. PCR reactions were carried 
out at 60°C using KOD polymerase (Merck Millipore). Mature pediocin was 
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generated using primers 6 and 7 (Table 5.1.).  The pedB, (specifies immunity) 
pedC and pedD (gene products are membrane bound proteins required for 
peptide secretion) (Horn et al., 1998) genes were amplified from P. acidlilacti 
DPC 5492 DNA using primers 7 and 8 (Table 5.1.). The restriction sites Pst1and 
Kpn1 were incorporated into the sequence to allow incorporation into the 
plasmid pNZ44 via a ligation reaction. Restriction polymerases and T4 DNA 
ligase were purchased from New England Biolabs (240 County Rd., Ipswich, 
MA, USA). Plasmid constructs were transformed into competent E.coli which 
was spread plated on LB agar containing 10 µg/ml chloramphenicol and 
incubated overnight. Successful transformants were treated with a Qiagen 
Plasmid Mini kit (Qiagen). Electrocompetent L. paracasei NFBC 338 cells were 
prepared using 3.5X SMEB (1M sucrose, 3.5mM MgCL2), as previously 
described by (Luchansky 1988). Plasmids were electroporated into L. paracasei 
NFBC 338 which was plated as described earlier with the addition of 10 µg/ml 
chloramphenicol. Correct nucleotide sequences were confirmed by Beckman 
Coulter Genomics (Essex CM22 6TA, United Kingdom)  
 
5.3.5. Peptide detection 
Strains were grown under conditions outlined above for ~17 h. Each 
sample was centrifuged at 4,000 g for 15 min and subsequently filtered through a 
0.22 nm syringe filter. Filter permeates were applied to a 3 ml, 200 mg C18 SPE 
column pre-equilibrated with methanol and water. The column was washed with 
3 ml 30% (v/v) ethanol, followed by 3 ml of 70% (v/v) isopropan-2-ol (IPA) 
0.1% trifluroacetic-acid (v/v) which was concentrated using a Centrivap 
Speedivac. Each sample was then applied to an analytical Jupiter Proteo RP-
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HPLC column (4.6 x 250 mm, 4µ, 90Å) (Phenomenex, Cheshire, UK) running a 
25% (v/v) to 55% (v/v) acetonitrile 0.1% (v/v) TFA gradient at 1 ml/min. Eluent 
was monitored at 214 nm and fractions were collected every minute. Relevant 
fractions were analysed for masses of interest using Matrix-assisted Laser 
Desorption/Ionization-Time of Flight (MALDI-TOF) Mass Spectrometry to 
visualize peptides of interest.  
 
5.3.6. Activity of heterologously generated antimicrobial peptide 
The agar well diffusion method (Ryan, Rea, Hill, & Ross, 1996) was 
used to determine the antimicrobial activity of Lb. paracasei NFBC 338 derived 
pediocin. Culture supernatants were adjusted to pH. 6.5 1 N NaOH and filter-
sterilized (0.45 µm). Antimicrobial activity was assessed using the indicator 
strain Listeria innocua DPC 3572. Agar plates were incubated appropriately 
overnight prior to examination for zones of inhibition.     
 
5.3.7. Evaluation of the bioactivity of Lb. paracasei DPC 6770 generated 
KGLP-1  
Incretin hormone production was first assayed using a MSD Total GLP-
1 plate (Cat. No.  K150JVC-1) as per the manufacturer’s instructions. 
Insulinotropic properties of L. paracasei DPC 6770 generated peptides were 
investigated using a method previously described (Salvucci, Neufeld, & 
Newsholme, 2013) with minor alterations. Briefly 2 ml of RINm5F β-cells were 
cultured as described in section 2.3. Cell monolayers were washed using 
KREBS-Ringer bicarbonate buffer (Sigma Aldrich) and starved for 40 min at 
basal glucose level via addition of 1 ml of KREBS buffer containing 1.1 mM 
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glucose (Sigma). Buffer was removed and the cells were stimulated with 
prepared filtrate from L. paracasei NFBC 338, DPC 6770 and DPC PED. Each 
sample was incubated with glucose at 2.2 mM, 4.4 mM or 8.8 mM glucose for 20 
min. Sigma GLP-1 and synthetic KGLP-1 were also assayed at concentrations of 
50 µmol, nmol and pmol for comparison. Following incubation samples were 
collected and treated with protease and phosphatase inhibitor (10 ul/ml) (Fisher 
Scientific UK Ltd, Bishop Meadow Road, Loughborough, UK.) (Cat. No. 
PN78443) before application to a MSD insulin plate (Cat. No. K152BZC-1). 
Insulin production was measured according to manufacturer’s instructions using 
a MSD Sector 2400.  
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5.4. Results 
5.4.1. Background 
L. paracasei NFBC 338 was used to generate recombinant strains as it was 
intestinally derived and has been previously shown as safe for human 
consumption (McGee, Bakens, Wiley, Riordan, & Webster, 2011). L. paracasei 
NFBC 338 has also been commercialized as a probiotic culture in cheese 
(Collins, Fitzgerald, O'Sullivan, Ross, & Stanton, 2005) and therefore was 
deemed an appropriate candidate for our study. We investigate whether the 
production and excretion machinery for the bacteriocin pediocin would be 
suitable to generate the recombinants. Prior to functional studies, the presence of 
relevant DNA fragments in the recombinants by restriction endonucleases and 
subsequent gel electrophoresis was confirmed. Correct DNA sequences were 
validated by DNA sequencing (data not shown). 
 
5.4.2. Expression of heterologous bioactive peptides  
The molecular mass of KGLP-1 and pediocin as indicated by MALDI-
TOF mass spectrometry showed peaks of 3512.68 Da and 4625.21 Da 
respectively, the appropriate molecular weights for both peptides (Fig. 5.1.). 
While GLP-1 has a molecular weight of approximately 3352.67-3358.67 Da, the 
amino acid sequence changes in KGLP-1 cause it to have a higher molecular 
weight. Cell lysis procedures were not required to detect the heterologous 
peptides in the cell-free supernatants indicating successful secretion by the 
recombinant Lb. paracasei strains. Well diffusion assays showed that the 
pediocin generated by L. paracasei DPC PED maintained antimicrobial activity 
against L. innocua comparable to that of P.  acidilactici DPC 5492 (2560 mAU), 
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while the control strains did not inhibit growth of L. innocua (Fig. 5.2.).  MSD 
Total GLP-1 plate demonstrated that L. paracasei DPC 6770 generated 
approximately 3854 pg/ml (40 µg/L) of KGLP-1 (Fig. 5.3.). Doubling the 
incubation time of L. paracasei DPC 6770 led to a lower level of detectable 
KGLP-1 peptide indicating some degradation over time. The controls strains did 
not produce any detectable levels of these peptides.        
 
5.4.3. Evaluation of in vitro insulinotropic properties of heterologous 
KGLP-1 
The insulinotropic effect of L. paracasei DPC 6770 generated KGLP-1 
was analysed and the results are outlined in Figure 5.4.. KGLP-1 compared 
favourably with synthetic GLP-1 and KGLP-1 at levels of 50 pmol, higher than 
post-prandial levels of GLP-1 in circulation in vivo (Holst, 2007). Glucose 
concentration did not appear to have an effect on the L. paracasei DPC 6770 
generated KGLP-1. Synthetic KGLP-1 compared favourably with Sigma 
Standard GLP-1 7-37.    
 
 
 
 
 
 
 
 
 
 186 
5.5  Discussion 
 The therapeutic potential of GLP-1 has been recognised in recent years 
due to its spectrum of physiological actions particularly with regard to diabetes. 
As well as stimulating insulin secretion in the body, GLP-1 also stimulates 
insulin gene expression, inhibits glucagon secretion (Drucker & Nauck, 2006; 
Gao et al., 2009) and reverses diabetes associated defects in the β cell within the 
pancreas (Egan, Bulotta, Hui, & Perfetti, 2003). The hormone also influences 
food intake, promoting gut satiety and delaying gastric emptying (Gao et al., 
2009; Gutzwiller et al., 1999; Holst, 2007). Importantly, unlike other 
antihyperglycemic treatments GLP-1 does not induce hypoglycaemia which is an 
issue with some diabetic medications, as the actions of the hormone are glucose 
dependent (Gao et al., 2009; Nathan, Schreiber, Fogel, Mojsov, & Habener, 
1992). GLP-1 also possesses a glucagonostatic effect that is of therapeutic 
relevance (Ebinger, Jehle, Fussgaenger, Fehmann, & Jehle, 2000). 
  Modifications of the initial histidine in the GLP-1 amino acid sequence 
have previously been evaluated and most convey DPP-IV resistance. However, 
the biological activity of these modified peptides can vary significantly due to a 
reduced affinity for binding to the GLP-1 receptor. The Xaa-Ala and Xaa-Pro 
dipeptides at the N-terminus of GLP-1 are the recognising sequence(s) for DPP-
IV. By extending the N-terminal of GLP-1 by attaching a Lysine to His
7 
significant DPP-IV resistance was achieved whilst maintaining potent 
insulinotropic activity comparable to native GLP-1. In their study, Gao et al. 
(2009) encapsulated KGLP-1 in long acting sustained release micro-spheres 
which following injection into diabetic rats lowered glucose and led to insulin 
release for almost 10 days (Gao et al., 2009). Sustained release of any GLP-R 
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agonist is important, as even if the agonist is resistant to DPP-IV degradation, 
renal clearance would still be an issue. In this present study, we used molecular 
cloning techniques to enable KGLP-1 and pediocin generation and secretion by 
an intestinally-derived Lactobacillus. Heterologous production of bacteriocins 
using recombinant microbial systems is seen as a way to improve production 
costs in instances where the natural producer generates an unsatisfactory yield or 
where the generation of synthetic peptides is cost prohibitive (Cintas, Herranz, & 
Hernández, 2011). Heterologous expression of bacteriocins can be achieved by 
exchanging leader peptides and/or dedicated ABC secretion and exporting 
systems as well as by adding signal peptides recognised by general secretory 
peptides (Richard, Drider, Elmorjani, Marion, & Prévost, 2004).  
  In our study, using PCR, OE-PCR, and SOE-PCR we were able to 
amplify the required genes from a Pediococcus, synthesize the nucleotide 
sequence responsible for KGLP-1 and combine the genes in a constitutive 
expression vector respectively. By incorporating the genes responsible for 
pediocin production and export into the pNZ44 expression vector and 
transforming into L. paracasei NFBC 338, we generated two strains capable of 
heterologous peptide production with potential benefits for human health. L.  
paracasei NFBC 338 was viewed as suitable candidate for transformation due to 
its probiotic, generally regarded as safe (GRAS) status, ability to survive spray-
drying at an industrial level (Gardiner et al., 2002) and its ability to survive the 
mammalian intestine and colonize the mammalian intestinal epithelium (McGee 
et al., 2011; Stanton, Ross, Fitzgerald, & Collins, 2001). In vitro functional 
testing demonstrated the activity of both heterologously produced peptides. 
Recombinantly generated pediocin compared favourably to the natural peptide 
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against L. innocua in well-diffusion assays indicating no reduction in bacteriocin 
potency or production. Our results indicated that approximately 3854 pg/ml of 
KGLP-1 were produced by L. paracasei DPC 6770 which has previously been 
shown to be of biological significance in vivo when administered per kg of 
bodyweight (Gao et al., 2009) . Functional testing using Rinm5f β-cells showed 
that L. paracasei DPC 6770 generated KGLP-1 led to significantly higher levels 
of insulin production compared to controls. Although the insulin production was 
not glucose dependent, Rinm5F β-cells, while seen as a good in vitro model of 
insulin production, have previously reported glucose insensitivity issues (Praz et 
al., 1983; Skelin, Rupnik, & Cencic, 2010). Synthetic KGLP-1 had an effect on 
insulin production by the cells similar to the effect seen using Sigma native GLP-
1 with both peptides stimulating insulin production in a dose dependant manner 
save for Sigma GLP-1 at a nanomolar concentration which may be due to assay 
sensitivity 
Diabetes is one of the major chronic diseases affecting people today 
(Pontarolo et al., 2013) and it’s prevalence is expected to double to ~300 million 
within the next 20 years (Verspohl, 2012). Populations across all stages of social 
and economic development are observing this increase of diabetes. Various 
factors such as increased urbanization, decreased physical activity and high-
calorie diets all contribute to higher frequencies of obesity, a major predisposing 
factor for diabetes (Mokdad et al., 2003; Pontarolo et al., 2013). The fact that 
diabetes has become the seventh leading cause of death in the U.S.A. illustrates 
the severity of this problem (Pontarolo et al., 2013). Numerous pharmacological 
treatments have been developed to treat diabetes and have been reviewed 
sufficiently elsewhere (Corless, Kiely, McClenaghan, Flatt, & Newsholme, 2006; 
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Pontarolo et al., 2013; Tahrani, Bailey, Del Prato, & Barnett, 2011; Verspohl, 
2012). Of particular note to our research are the extensive recent investigations 
into the use of treatments based on incretin hormones capable of acting as GLP-1 
receptor agonists. Exenatide a synthetic form of Gila monster derived exendin-4 
shares -53% homology to endogenous GLP-1 and was the first approved GLP-1 
receptor agonist. Current treatment requires twice daily subcutaneous 
administrations of 5 or 10 mg. A once weekly formulation has recently been 
approved for treatment by the FDA (Buse et al., 2012). Liraglutide is another 
GLP-1 receptor agonist approved for treatment of type 2 diabetes. It shares 97% 
amino acid sequence identity with native GLP-1 and is 99% albumin bound, as 
free liraglutide is degraded by endogenous peptidase action in vivo. Liraglutide 
administered once daily enables significantly better glycaemic control compared 
to twice daily exenatide administration. Longer acting sustained release 
formulations are currently being researched to improve the convenience of 
treatments (Buse et al., 2012; Pontarolo et al., 2013).  
  The gut microbiota can exert profound effects on human health 
(Clemente, Ursell, Parfrey, & Knight, 2012). The methods we have outlined in 
our study could be used to tailor microbes with specific host interactions to 
improve overall health using bacteriocin export machinery to generate 
heterologous peptides, with L paracasei DPC 6770 being an example of a 
potential treatment for diabetes. Further analysis will have to be undertaken to 
confirm the efficacy of L. paracasei DPC 6770 in vivo although its ability to 
produce biologically-significant amounts of insulinotropic peptide and the 
ability of  native L. paracasei NFBC 338 to survive industrial processing and gut 
passage make it a promising candidate for use as a diabetes treatment. In vivo 
 190 
studies could confirm the levels of KGLP-1 produced by L. paracasei DPC 6770 
in the gut, the amount of peptide crossing into the bloodstream and the effect 
upon the subject with regard to blood glucose levels. A treatment strategy using 
a recombinant probiotic microbe producing the incretin hormone avoids issues 
such as the expense incurred in peptide synthesis (Cintas et al., 2011) and the 
difficulty caregivers have persuading patients to comply with therapies that 
involve multiple injections (Pontarolo et al., 2013). Additionally the 
recombinant strain may also aid in a reduction in weight, which is particularly 
important in the early stages of diabetes treatment due to the appetite regulating 
activity of GLP-1.   
  In conclusion, we have generated a recombinant strain of an intestinal 
organism which produces a human gut hormone using bacteriocin machinery 
This indicates the potential for this method to be used to generate further 
recombinant strains capable of producing other bioactive peptides.  
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Table 5.1. Oligonucleotides used in plasmid construct generation 
Primer 
number Nucleotide sequence 5'-3' 
1 
GGCCAATATCATTGGTGGTAAGCATGTGGAAGGCACCTTTACCAGCGATGTGAGCAG
CTATCTGGAAGGCCAGGCGGC  
2 
CCGCTCGAGTTAGCCGCGGCCTTTCACCAGCCACGCAATAAATTCTTTCGCCGCCTG
GCCTTCCAGATAGCTGCTCAC 
3 AATCGGCGCCGGAAAG 
4 TTCGTACACCTTCCGTGG 
5 ACATCCATGGAAGAAGAAGGAGATTTTTG 
6 GCACCTGCAGGCTAGCATTTATGATTAC 
7 GCACCTGCAGCATTATGCTGAGCTGGCATC 
8 GCACGGTACCGCGAGGATTTCACGG 
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Figure 5.1. MALDI-TOF mass spectra indicating position of relevant peptide 
peaks. (A) MRS media control. (B) Wild-type Lb. paracasei NFBC 338 filtrate. 
(C) Lb. paracasei DPC 6770 filtrate; oval indicates position of KGLP-1 peptide. 
(D) Lb. paracasei DPC PED filtrate; oval indicates position of pediocin peptide.   
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Figure 5.2.Well diffusion assay demonstrating pediocin production against L. 
innocua by Lb. paracasei DPC PED at 2560 mAU (A) and Lb. paracasei DPC 
6770 control showing zero inhibition (B).  
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Figure 5.3. GLP-1 production as measured by a MSD Total GLP-1 plate. Lb. 
paracasei DPC 6770 production of GLP-1 after 24 and 48 h compared to control 
strains. 1000, 333 and 111 pg/ml are total GLP-1 standards supplied by kit 
manufacturer.  
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Figure 5.4. Insulin production (pg/ml) by Rinm5F-Beta cells treated with 
various cell filtrate preparations and purified KGLP-1 and GLP-1 at varying 
glucose concentrations with Lb. paracasei DPC 6770 compared to non-
insulinotropic control strains and purified standards.  
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Nutrition for growth and maintenance of the body have been considered 
the principal role of food since time immemorial. The fact that certain foods 
can cause further beneficial physiological effects post-consumption has led to 
an increase in research on the identification and characterisation of the specific 
components responsible for these benefits. Due to the extra benefits and 
various biological functions these food components may have, the term 
Functional Foods is often used to describe them. While a globally accepted 
definition has not yet been agreed on, Functional Food foods are broadly 
regarded as “generally consumed foodstuffs that (may) provide added health 
benefits following the addition/concentration of a beneficial ingredient, or the 
removal/substitution of an ineffective or harmful ingredient” (FSAI, 2007). 
The Functional Food market is currently estimated to be worth  over $40 
billion worldwide, and it is showing steady annual increases both in sales and 
new products launched (Valls et al., 2013). Both probiotics and bioactive 
peptides represent an important component of this functional food market.  
Food-derived bioactive peptides can be generated via bacterial fermentation or 
enzymatic hydrolysis. Other methods may also be used to generate and deliver 
peptides with beneficial properties however. This thesis details the generation 
of peptides by bacterial fermentation, enzymatic hydrolysis and the use of 
recombinant molecular techniques highlighting industrially relevant ways to 
generate peptides.  
The emergence of Cronobacter as an important pathogen has led to an 
increase in research on the genus. Since it’s reclassification from Enterobacter 
sakazakki to the genus Cronobacter, molecular research has led to the 
classification of 10 separate species (Holý & Forsythe, 2014; Iversen et al., 
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2007; C. Iversen et al., 2008; Carol Iversen et al., 2008; Joseph et al., 2012). 
Investigations have to date identified particularly pathogenic strains of the 
organism and specific associated virulence factors (Holý & Forsythe, 2014; 
Stephan, Lehner, Tischler, & Rattei, 2011). These factors include proteolytic 
enzyme production, toxin production, adherence mechanism relevant to the 
gastro-intestinal tract, ability to cross intestinal and blood brain barriers and 
immune response evasion (Jaradat, Al Mousa, Elbetieha, Al Nabulsi, & Tall, 
2014). The increase in knowledge of the genus, in particular, is allowing a 
better understanding of methods to prevent illness caused by Cronobacter. As 
infants are the group principally affected by infection, and powdered infant 
formula is the food most associated as the transmission vehicle, there is an 
urgent need for the development of natural and safe antimicrobials for use in 
this product. To date a number of candidates have arisen which could help 
improve the safety of PIF. These include bioactive peptides, organic acids and 
probiotic bacteria (Chapter 1).  The initial aim of this thesis was the generation 
of milk-derived bioactive peptides with antimicrobial activity against 
Cronobacter strains. The thesis describes two novel methods to achieve this, 
and also expands by describing a third method of peptide generation, in which 
a recombinant lactobacilli produced a biologically active peptide. 
The advent of high-throughput bacterial genome sequencing has 
significantly advanced the ease and cost with which it was once associated. 
This phenomenon can be exploited to rapidly analyse bacterial strains (Loman 
et al., 2012). In Chapter 2 of this thesis the genome of Lactobacillus johnsonii 
DPC6026, an isolate from the porcine gastrointestinal tract (Hayes, Ross, 
Fitzgerald, Hill, & Stanton, 2006) was sequenced and annotated. This strain 
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was previously used to generate antimicrobial peptides via fermentation in 
bovine casein (Hayes, Ross, Fitzgerald, Hill, & Stanton, 2006). In this chapter, 
the strain was compared to other lactobacilli, particularly the to the human gut 
isolate L. johnsonii NCC533 (Pridmore et al., 2004). The results indicated a 
number of differences between the strains, most noticeably a large symmetrical 
inversion of approximately 750kb across the replication axis. Eight other 
porcine L. johnsonii strains investigated in this study possessed the same 
genome structure as L. johnsonii DPC6026 while a single human isolate L. 
johnsonii ATCC12088, harboured the same genomic arrangement as L. 
johnsonii NCC533 with respect to the insertion. This study highlighted 
significant variation with regards cell protection mechanisms, adhesion 
proteins and putative phage resistant mechanisms reflecting host-specific 
divergence of L. johnsonii strains. There was however, a relatively conserved 
homogeneity in core regions of the genomes of the bacteria studied. L. 
johnsonii DPC6026 was found to possess a type III resistance modification 
system, which was not previously identified in L. johnsonii. This system 
coupled with a novel clustered regularly interspaced short palindromic repeats 
(CRISPR)-cas system suggests significant past exposure of the strain to phage 
in its ecological niche(s).   
Chapter 3 describes a method to generate antimicrobial peptides 
(AMPs) capable of inhibiting Cronobacter growth from bovine casein using a 
Bacillus strain. Bacillus species are the predominant bacteria used during 
industrial fermentations and for commercial enzyme production (Rao, 
Tanksale, Ghatge, & Deshpande, 1998). In this study, 12 Of the 16 strains 
investigated demonstrated potent proteolytic activity when tested on a  casein 
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substrate. Most of these strains were isolated from a dairy environment while 
four, which were incapable of breaking down casein, were isolated from a soil 
or unreported environment, save for Bacillus coagulans LMG6326 (a milk 
powder isolate). Interestingly, only strains from the species Bacillus cereus and 
Bacillus thuringiensis were capable of generating the antimicrobial peptides 
caseicin A and B. B. cereus and B. thuringiensis, along with Bacillus anthracis 
are members of the group I bacilli and are very closely related (Radnedge et 
al., 2003). Previous investigations of B. cereus and B. thuringiensis have 
shown a very similar protease complement dominated by members of the 
thermolysin-like M4 family of peptidases and neutral protease (Npr) enzymes 
which may indicate why representatives of these two species generated the 
same peptides. As the main target for an antimicrobial would be infant formula, 
the strict regulatory conditions associated with the product should be taken into 
account. As milk proteins possess a long history of safe use and are a 
permissible ingredients in formula (CAC, 2007), they stand as an acceptable 
and natural source of antimicrobials (Benkerroum, 2010; Nagpal et al., 2011). 
However, an issue here is the permissibility of the use of some Bacillus strains 
as a culture to generate them. For this reason, Bacillus species are used less 
frequently in fermentations to generate bioactive peptides when compared to 
Lactic Acid Bacteria (LAB). Although this study focused exclusively on the 
generation of caseicin A and B, further research examining various peptides 
generated via bacterial fermentation with proteolytic strains such as those 
utilized in this work may lead to the discovery of other bioactives. In order to 
be of use in an industrial context, the generation of bioactive peptides must be 
reproducible and cost efficient (Ross, Stanton, Hill, & Fitzgerald, 2007). The 
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use of strains such as those used in this study, which do not require complex 
media, pH control and an anerobic environment offer advantages over more 
fastidious bacteria from a cost perspective. Although this work focused 
exclusively on the generation of caseicin A and B, further research examining 
fermentates generated with other proteolytic Bacillus strains is warranted. 
 Due to the current regulatory concerns regarding the use of Bacillus 
strains to generate a preservative for infant formula, a food-grade technique to 
generate the caseicin peptides using in-silico methods and industrial enzymes 
was developed. Well maintained and updated online peptide databases have 
increased the potential and feasibility of predicating new bioactive peptides 
prior to the initiation of laboratory synthesis. Combining this technique with 
enzymatic hydrolysis is a sensible approach to peptide generation. The 
majority of known bioactives have been identified via hydrolysis with the 
gastric enzymes, trypsin and pepsin (Korhonen & Pihlanto, 2006). This makes 
sense from an evolutionary perspective as naturally consumed proteins are 
hydrolysed by these enzymes. The use of enzymes from other sources has been 
researched to a lesser degree however. In this study, the protease complement 
of B. cereus and B. thuringiensis were first examined through analyses of their 
genome sequences. The subsequent in-silico analysis of the enzymes revealed 
that the M4 family of peptidases were likely responsible for casein degradation 
(Chapter 4). Although a perfect match for caseicin production was not 
identified, the in-silico portion of this study removed the requirement to screen 
a vast bank of enzymes and focus on Enzyme Commission (E.C.) 3.4.24.28 
(bacilliolysin) and EC 3.4.24.27 (thermolysin-like enzymes). These neutral 
metalloprotease enzymes display broad specificity but specifically cleave at 
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hydrophobic amino acids within the protein sequence (Večerek & Venema, 
2000). Interestingly, every enzyme examined in this study efficiently 
hydrolysed the casein. Only enzymes derived from Bacillus 
thermoproteolyticus were capable of generating casein A. A thermolysin from 
a fungal source, although similar in structure, did not generate the peptide 
following exposure. Thermoase PC10F (Genencor, Rochester, NY, USA) 
hydrolysed casein into small peptides but 4 h incubation (37-65⁰C) was 
required to allow detection of caseicin A peaks by Matrix-assisted laser 
desorption Time-of-Flight Mass Spectrophotometry indicating that some 
secondary hydrolysis was required. Reverse Phase High-Performance Liquid 
Chromatography indicated that the yield generated by enzymatic hydrolysis 
was 9-11 times greater than previously observed during bacterial fermentations 
(Chapter 2). The process was also increased to pilot (10 L) scale without a 
reduction in % yield. Thermolytic-liberated caseicin A was found to have an 
MIC of 0.625 mM which is identical to the MIC achieved with the synthesised 
peptides in this study and in previous work (Norberg et al., 2012). A powder 
generated from a filtrate of the enzymatic hydrolysate also maintained 
antimicrobial activity, slowing the growth of the pathogenic strains assayed in 
infant formula. A major issue with bioactive peptide development is the 
prohibitive cost of manufacture (Marr, Gooderham, & Hancock, 2006). 
Research is on-going into ways to improve the feasibility of industrial 
production. A number of novel technologies applicable at such a scale, such as 
ion exchange chromatography and new methods of membrane separation are 
now being employed by the dairy ingredients industry (Korhonen, 2009; 
Korhonen & Pihlanto, 2006). These methods are seen as suitable ways to help 
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enrich bioactive peptide fractions of dairy hydrolysates. The methods outlined 
in this chapter in which the release of specific peptides is directed by prior in-
silico investigations can streamline the generation of peptides and increase the 
amount of potential functional food products.  
There currently exists a growing global trend of increasing obesity and 
diabetes levels. Indeed factors such as increased urbanization and high calorie 
diets are leading to a rise in the incidence of diabetes at all socio-economic 
levels across different populations (Ford, Giles, & Mokdad, 2004; Pontarolo et 
al., 2013). Bioactive peptides are recognised as having a broad range of 
physiological activities in-vivo. Development of peptide based products which 
aid the management of factors such as hypertension, blood glucose levels and 
body mass indices (BMIs), which are associated with metabolic syndrome have 
tremendous potential to improve consumer health. Many diabetes sufferers use 
insulin to manage type-1 and type-2 diabetes mellitus (TODM and TTDM 
respectively) and currently there exists more than 20 different insulin products 
in the United States (http://www.diabetes.org/living-with-diabetes/treatment-
and-care/medication/insulin/). There are a number of drawbacks to this 
treatment, such as overdose which can lead to life-threatening hypoglycaemia 
(Svingos, Fernandez, Reeder, & Parker, 2013) and poor adherence to therapy 
regimes by patients (Peyrot, Barnett, Meneghini, & Schumm‐Draeger, 2012). 
In the healthy body, insulin secretion by the pancreas is potentiated principally 
by the action of two incretin hormones, glucose-dependent insulinotropic 
polypeptide (GIP) and Glucagon-like peptide-1 (GLP-1). GLP-1 in particular 
has been the subject of intense research as a novel therapy for TTDM 
(Pontarolo et al., 2013). There are currently a number of GLP-1 based 
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therapies available and long-acting sustained release formulations are currently 
being developed (Buse et al., 2013; Pontarolo et al., 2013). In Chapter 5 of this 
thesis, molecular methods were used to generate two peptide generating 
recombinant lactobacilli. Our results indicated that the GLP-1 analogue 
generated by one of the recombinants possessed insulinotropic activity in-vitro. 
Although this study focused specifically on a treatment for diabetes, the 
method outlined can be used to incorporate other bioactive peptides into 
expression systems and possibly tailor treatments for specific medical 
conditions such as hypotension and improved cognitive functions. 
  Bioactive peptides are the subject of increasing interest for use in 
functional foods. However there is a need to demonstrate their efficacy in 
human clinical trials at doses that can be generated in a food vehicle 
economically. The study outlined in Chapter 3 highlights the potential of 
Bacillus to be used for bioactive peptide generation via fermentation. Bacillus 
species are often viewed as spoilage organism, particularly in the dairy 
industry. However, the inherent proteolytic ability possessed by many of these 
strains can be utilized to generate peptide fragments with potential 
bioactivities. Chapter 4 demonstrated the potential in-silico techniques have to 
streamline production of peptides. Moreover, the enzymatic method used in 
this chapter yielded a much higher amount of the antimicrobial of interest in 
comparison to bacterial fermentation. The findings of Chapter 5 describe not 
only a potential TTDM treatment, but also a method to generate probiotic 
bacteria producing physiologically relevant peptides. This thesis describes 
bioactive peptide generation via bacterial fermentation, targeted enzymatic 
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hydrolysis and recombinant bacteria contributing to the development of 
technologies which allow for peptide discovery and industrial-scale production.  
 Further investigations should be undertaken to elucidate the bioactive 
peptide generation capabilities of underutilized bacterial species such as 
Bacillus. This could be aided by or indeed be the starting point of studies like 
that describe in Chapter 4 of this thesis. The high level of proteolysis observed 
in casein protein during the investigations described in this work led to the 
generation of numerous peptides which may possess physiologically beneficial 
bioactivities. The techniques described could be utilized in with other protein 
sources, such as the milk protein whey, or protein from meat of plant source. 
The results observed in Chapter 5 of this work are promising with regards a 
TTDM therapy. However, in-vivo analysis, particularly human trials are 
required to fully validate the functionally and efficacy of the recombinant 
strain. As the peptide influences more than just insulin production, effects on 
aspects such as satiety would be investigated.  
 To conclude, the work described in this thesis specifically outlines two 
novel methods to generate anti-Cronobacter bioactive peptides as well the 
generation of a recombinant lactobacilli which produced an active 
insulinotropic peptide. In a broader sense, the thesis contributes to the field of 
bioactive peptide discovery by describing novel methods for their generation.  
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